<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2022.1095879</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Placental macrophages present distinct polarization pattern and effector functions depending on clinical onset of preeclampsia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mercnik</surname><given-names>Monika Horvat</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2046314"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schliefsteiner</surname><given-names>Carolin</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/425393"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fluhr</surname><given-names>Herbert</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2162423"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wadsack</surname><given-names>Christian</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/426461"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Obstetrics and Gynaecology, Medical University of Graz</institution>, <addr-line>Graz</addr-line>, <country>Austria</country></aff>
<aff id="aff2"><sup>2</sup><institution>BioTechMed-Graz</institution>, <addr-line>Graz</addr-line>, <country>Austria</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Ruoxi Yuan, Hospital for Special Surgery, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Poonam Dhillon, University of Pennsylvania, United States; Xinjun Wu, University of North Carolina at Chapel Hill, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Christian Wadsack, <email xlink:href="mailto:christian.wadsack@medunigraz.at">christian.wadsack@medunigraz.at</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Inflammation, a section of the journal Frontiers in Immunology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>12</day>
<month>01</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>1095879</elocation-id>
<history>
<date date-type="received">
<day>11</day>
<month>11</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>12</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Mercnik, Schliefsteiner, Fluhr and Wadsack</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Mercnik, Schliefsteiner, Fluhr and Wadsack</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Hofbauer cells (HBCs) are resident macrophages of the human placenta, regulating immune tolerance and tissue homeostasis. HBCs of a normal placenta (CTR) exhibit mainly an anti-inflammatory M2 phenotype. Under exaggerated chronic inflammation during pregnancy, as in preeclampsia (PE), a phenotypic switch towards M1 polarization has been proposed. PE, defined as maternally derived syndrome can be distinguished into two different entities: early-onset (EO) preeclampsia and late-onset (LO) preeclampsia. Although the clinical presenting characteristics overlap, both can be identified by biochemical markers, heritability, and different maternal and fetal outcomes. To date, no study has specifically investigated polarization and phenotype of EO- and LO-PE HBCs and looked at possible changes in HBC functionality. Primary HBCs were isolated from CTR and PE placentae. First, <italic>in vitro</italic> morphological differences were observed between CTR and PE HBCs, with both PE groups exhibiting features of M1 macrophages alongside M2 forms. Interestingly, a different polarization pattern was observed between EO- and LO-PE HBCs. EO-PE HBCs develop a tissue remodeling M2 phenotype that is strongly shifted toward M1 polarization and showed a significant upregulation of CD86, TLR4, and HLA-DR. Furthermore, this pro-inflammatory signature is corroborated by higher expression of IRF5 and of <italic>NOS2</italic> (p &#x2264; 0.05). However, their M2 characteristics is reflected by significant TGF-&#x3b2; secretion and <italic>ARG1</italic> expression. In contrast, LO-PE HBCs developed a phagocytic CD209-low M2 phenotype in which the M1 pattern was not as pronounced as they downregulated the <italic>NOS2</italic> gene, but expressed increased levels of pro-inflammatory CD80 and TLR1 (p &#x2264; 0.05). The enhanced phagocytosis and MMP-9 secretion alongside the increased secretion of anti-inflammatory IL -4, IL -13 and TGF-&#x3b2; in both EO- and LO-PE HBCs suggests their adaptive role and plasticity in resolving inflammation and tissue homeostasis.</p>
</abstract>
<kwd-group>
<kwd>hofbauer cell</kwd>
<kwd>preeclampsia</kwd>
<kwd>polarization</kwd>
<kwd>early onset preeeclampsia</kwd>
<kwd>late onset preeclampsia</kwd>
<kwd>inflammation</kwd>
<kwd>macrophage</kwd>
<kwd>human placenta</kwd>
</kwd-group>
<contract-num rid="cn001">Doc 31-B26</contract-num>
<contract-sponsor id="cn001">Austrian Science Fund<named-content content-type="fundref-id">10.13039/501100002428</named-content>
</contract-sponsor>
<counts>
<fig-count count="6"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="112"/>
<page-count count="14"/>
<word-count count="10225"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Preeclampsia is a maternally derived inflammatory syndrome, affecting 4-5% of pregnancies worldwide. It is a leading cause of preterm delivery and intrauterine growth restriction, mainly due to the insufficient nutrient supply across the placenta and chronic hypoxia exposure of the fetus (1, 2). PE is clinically defined as <italic>de novo</italic> onset of hypertension (&#x2265;140/90 mmHg) accompanied by one or more of the following new-onset conditions: proteinuria, thrombocytopenia, renal failure, impaired liver function, pulmonary edema, neurological complications, or uteroplacental dysfunction, occurring after 20 weeks of gestation (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B3">3</xref>). Depending on the time of diagnosis, this syndrome can be divided into two subgroups, namely before (early-onset, EO) or after (late-onset, LO) 34 weeks of gestation (<xref ref-type="bibr" rid="B4">4</xref>&#x2013;<xref ref-type="bibr" rid="B6">6</xref>). PE is a complex and heterogeneous disorder whose pathophysiological mechanisms are still not fully understood (<xref ref-type="bibr" rid="B7">7</xref>). Of note, different aetiology of EO- and LO-PE has been suggested. Briefly, EO-PE is associated with placental dysfunction and is more likely to affect the fetus (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>), whereas LO-PE is mediated by maternal factors, therefore more favourable for successful fetal outcome (<xref ref-type="bibr" rid="B10">10</xref>). The placenta in PE is characterized by profound morphological and functional alterations (<xref ref-type="bibr" rid="B11">11</xref>), due to poor placentation and placental ischemia (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>). In addition, placental dysfunction has been associated with an imbalanced immune function, excessive inflammation accompanied with increased production of pro-inflammatory factors, and simultaneously a decrease in the number of regulatory immune cells and anti-inflammatory cytokines, all together contributing to the development and progress of PE (<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B16">16</xref>).</p>
<p>Both the maternal and feto-placental immune system play a crucial role in the development of pregnancy (<xref ref-type="bibr" rid="B16">16</xref>). Hence, in contrast to normal pregnancy, where the immune systems contribute to the maintenance of feto-maternal tolerance and placental development, a pro-inflammatory environment leads to excessive activation of innate immune cells and consequently to placental dysfunction and/or poor maternal vascular adaptation (<xref ref-type="bibr" rid="B16">16</xref>&#x2013;<xref ref-type="bibr" rid="B19">19</xref>). Macrophages represent a diverse group of innate immune cells, vital for the regulation of inflammation, tissue homeostasis, and defence (<xref ref-type="bibr" rid="B20">20</xref>). Due to their remarkable plasticity that allows them fast and direct response to the stimuli and to the adaptive capability of their micro-environmental milieu (<xref ref-type="bibr" rid="B21">21</xref>), they are important key players in the progression of pregnancy and could be involved in the development and progression of PE (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B19">19</xref>). Macrophages are keen to develop a broad spectrum of phenotypes along the M1 and M2 axis, which allows to divide the cells into defined classical M1 and M2 polarized groups (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>) The balance between the different polarization states often plays an important role in the resolution or progression of inflammation (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>). Their phenotypic heterogeneity is also reflected in their effector functions. In general, M1 macrophages are thought to be pro-inflammatory, while M2 macrophages limit inflammation and promote tissue repair, angiogenesis and homeostasis (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>).</p>
<p>Hofbauer cells (HBCs) are placental macrophages residing from day 18 after conception (<xref ref-type="bibr" rid="B28">28</xref>) in the chorionic villi of the human placenta (<xref ref-type="bibr" rid="B29">29</xref>). In a normal pregnancy HBCs are M2 polarized (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B30">30</xref>&#x2013;<xref ref-type="bibr" rid="B33">33</xref>) long spindled cells with large vacuoles (<xref ref-type="bibr" rid="B34">34</xref>). Due to their phenotypic heterogeneity, HBCs fulfil a variety of functions (<xref ref-type="bibr" rid="B35">35</xref>). As placental immune cells, they exhibit micro-biocidal activity (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>) and promote maternal tolerance towards the fetus (<xref ref-type="bibr" rid="B38">38</xref>). They are known to engage in tight and specific interactions with surrounding placental cells, therefore promoting trophoblast function (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B40">40</xref>), tissue remodeling (<xref ref-type="bibr" rid="B36">36</xref>) and angiogenesis (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>). Perturbations in the homeostatic functions of HBCs are often associated with inflammation (<xref ref-type="bibr" rid="B43">43</xref>&#x2013;<xref ref-type="bibr" rid="B46">46</xref>) and infection (<xref ref-type="bibr" rid="B47">47</xref>). Despite their crucial role in placental tissue, knowledge about the role of HBCs in PE is still lacking. A deeper understanding of HBC function offers the potential for therapeutical immune manipulation during compromised pregnancies in relation to gestational age, which determines both maternal and perinatal outcomes.</p>
<p>This study aimed to investigate polarization and phenotypic differences of primary human HBCs isolated from normal and PE placentae. In addition, we tested whether changes of the HBC phenotype might be linked to altered functionality, specifically to phagocytosis, tissue remodeling and the ability of macrophages to activate feto-placental endothelial cells (fpEC). Further, as gestational age has been identified as the most important clinical variable, we hypothesized that stratification of PE (EO-PE vs LO-PE) may account for the observed functional changes of HBCs within each group. These findings, while somewhat preliminary (due to case numbers), demonstrate that the inflammatory placental environment of EO-PE alters the immunoregulatory phenotype of HBCs with an increased pro-inflammatory M1 signature. Interestingly, LO-PE HBCs remained M2 polarized cells, but with a different polarization pattern as controls.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<label>2</label>
<title>Materials and methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Study population</title>
<p>In this study preeclampsia was defined according to the guidelines of the American College of Obstetricians and Gynaecologists as already mentioned above (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). The institutional ethics committee of the Medical University of Graz (29-319 ex 16/17) approved the study. Subjects included in the study signed an informed consent form before participation, the characteristics of which are shown in the <xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref>. Included placentae from singleton pregnancies were used within 30 minutes of caesarean section or vaginal delivery. PE was defined as a sustained blood pressure of 140/90&#xa0;mm Hg or greater (on two occasions at least 4 hours apart) occurring after 20 weeks of gestation in a woman with previously normal blood pressure, accompanied by one or more of the following new onset conditions: proteinuria, thrombocytopenia, renal insufficiency, impaired liver function, pulmonary edema, neurological complications or uteroplacental dysfunction. Onset of PE was defined as early (EO, delivered and detected before 34 weeks of gestation) or late (LO, delivered and detected after 34 weeks of gestation) (<xref ref-type="bibr" rid="B1">1</xref>). Placentae from normal pregnancies served as controls.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Subject characteristics of women and their offspring included in the study.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left"/>
<th valign="middle" align="center">CTR<break/>(n=22)</th>
<th valign="middle" align="center">EO-PE<break/>(n=8)</th>
<th valign="top" align="center">LO-PE<break/>(n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">Age</td>
<td valign="middle" align="center">29.4 &#xb1; 3.5</td>
<td valign="middle" align="center">34.4 &#xb1; 3.6 **</td>
<td valign="middle" align="center">34.4 &#xb1; 4.0 &#x2020;</td>
</tr>
<tr>
<td valign="bottom" align="left">BMI before pregnancy (kg/m2)</td>
<td valign="bottom" align="center">22.5 &#xb1; 2.9</td>
<td valign="bottom" align="center">21.0 &#xb1; 2.1</td>
<td valign="bottom" align="center">23.4 &#xb1; 3.2</td>
</tr>
<tr>
<td valign="bottom" align="left">Week of gestation</td>
<td valign="bottom" align="center">38.7 &#xb1; 1.5</td>
<td valign="bottom" align="center">34.2 &#xb1; 1.1 ****</td>
<td valign="bottom" align="center">37.7 &#xb1; 1.1</td>
</tr>
<tr>
<td valign="bottom" align="left">Mode of the delivery</td>
<td valign="bottom" align="center">SP 10/CS 12</td>
<td valign="bottom" align="center">CS 8</td>
<td valign="bottom" align="center">SP 3/CS 3</td>
</tr>
<tr>
<td valign="bottom" align="left">Fetal sex</td>
<td valign="bottom" align="center">8&#x2640; 14&#x2642;</td>
<td valign="bottom" align="center">4&#x2640;, 4&#x2642;</td>
<td valign="bottom" align="center">2&#x2640;, 4&#x2642;</td>
</tr>
<tr>
<td valign="bottom" align="left">Umbilical cord blood<break/>Arterial, pH</td>
<td valign="bottom" align="center">7.30 &#xb1; 0.06</td>
<td valign="bottom" align="center">7.31 &#xb1; 0.03</td>
<td valign="bottom" align="center">7.25 &#xb1; 0.09</td>
</tr>
<tr>
<td valign="bottom" align="left">Umbilical cord blood<break/>Venous, pH</td>
<td valign="bottom" align="center">7.37 &#xb1; 0.06</td>
<td valign="bottom" align="center">7.36 &#xb1; 0.02</td>
<td valign="bottom" align="center">7.34 &#xb1; 0.05</td>
</tr>
<tr>
<td valign="bottom" align="left">Placental weight (g)</td>
<td valign="bottom" align="center">616.7 &#xb1; 123.0</td>
<td valign="bottom" align="center">425.7 &#xb1; 63.7</td>
<td valign="bottom" align="center">506.7 &#xb1; 82.8</td>
</tr>
<tr>
<td valign="bottom" align="left">Birth weight (g)</td>
<td valign="bottom" align="center">3345 &#xb1; 398</td>
<td valign="bottom" align="center">1996 &#xb1; 404.7 ****</td>
<td valign="bottom" align="center">2955 &#xb1; 288.9</td>
</tr>
<tr>
<td valign="bottom" align="left">Birth weight percentile</td>
<td valign="bottom" align="center">49.2 &#xb1; 21.2</td>
<td valign="bottom" align="center">24.0 &#xb1; 18.7 **</td>
<td valign="bottom" align="center">34.3 &#xb1; 11.3</td>
</tr>
<tr>
<td valign="middle" align="left">Systolic blood pressure (mmHg)</td>
<td valign="middle" align="center">115.1 &#xb1; 6.9</td>
<td valign="middle" align="center">162 &#xb1; 12.1****</td>
<td valign="middle" align="center">153.2 &#xb1; 20.9 &#x2020;&#x2020;&#x2020;&#x2020;</td>
</tr>
<tr>
<td valign="middle" align="left">Diastolic blood pressure (mmHg)</td>
<td valign="middle" align="center">72.9 &#xb1; 10.2</td>
<td valign="middle" align="center">94.3 &#xb1; 8***</td>
<td valign="middle" align="center">103 &#xb1; 13.3 &#x2020;&#x2020;&#x2020;&#x2020;</td>
</tr>
<tr>
<td valign="bottom" align="left">sFlt-1 [pg/mL]</td>
<td valign="bottom" align="center">/</td>
<td valign="bottom" align="center">14472 &#xb1; 5083 &#x2021;</td>
<td valign="bottom" align="center">8257 &#xb1; 2881</td>
</tr>
<tr>
<td valign="bottom" align="left">PlGF [pg/mL]</td>
<td valign="bottom" align="center">/</td>
<td valign="bottom" align="center">66.2 &#xb1; 24.3</td>
<td valign="bottom" align="center">81.6 &#xb1; 13.02</td>
</tr>
<tr>
<td valign="bottom" align="left">sFlt-1/PlGF [pg/mL]</td>
<td valign="bottom" align="center">/</td>
<td valign="bottom" align="center">248.7 &#xb1; 118.1</td>
<td valign="bottom" align="center">105.5 &#xb1; 51.9</td>
</tr>
<tr>
<td valign="bottom" align="left">Platelets [109/L]</td>
<td valign="bottom" align="center">218.3 &#xb1; 63.1</td>
<td valign="bottom" align="center">221.9 &#xb1; 106.3</td>
<td valign="bottom" align="center">191.8 &#xb1; 60.8</td>
</tr>
<tr>
<td valign="bottom" align="left">Uric acid [mg/dL]</td>
<td valign="bottom" align="center">/</td>
<td valign="bottom" align="center">6.3 &#xb1; 1.4</td>
<td valign="bottom" align="center">5.9 &#xb1; 0.7</td>
</tr>
<tr>
<td valign="bottom" align="left">AST [U/L]</td>
<td valign="bottom" align="center">/</td>
<td valign="bottom" align="center">21.0 &#xb1; 6.3</td>
<td valign="bottom" align="center">21.2 &#xb1; 4.2</td>
</tr>
<tr>
<td valign="bottom" align="left">ALT [U/L]</td>
<td valign="bottom" align="center">/</td>
<td valign="bottom" align="center">17.4&#xb1; 5.6</td>
<td valign="bottom" align="center">12.7 &#xb1; 4.8</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>BMI, body-mass index; SP, spontaneous delivery; CS, caesarean section; All data are shown as mean &#xb1; SD. Statistical significance was assessed by one-way ANOVA with Tukey&#x2019;s <italic>post-hoc</italic> test. If normality testing failed, Kruskal-Wallis test with Dunn&#x2019;s <italic>post-hoc</italic> test was used. When comparing two groups&#x2019; Students t-test was used. **p &#x2264; 0.01, ***p &#x2264; 0.001 and ****p &#x2264; 0.0001; whereas *CTR vs EO-PE.  &#x2020;p &#x2264; 0.05 and &#x2020; &#x2020; &#x2020; &#x2020;p &#x2264; 0.0001; whereas &#x2020;CTR vs LO-PE.  &#x2021; represents comparison between EO-PE vs LO-PE; whereas &#x2021; p &#x2264; 0.05.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Isolation of HBCs</title>
<p>Primary HBCs were isolated according to a modified protocol as described by Tang et&#xa0;al. (<xref ref-type="bibr" rid="B48">48</xref>). To avoid contamination with decidual macrophages, the decidual membrane was removed before isolating HBCs. The villous tissue was dissected, washed in 0.4% saline solution (Fresenius, Cat #C924228), and finely minced. Between 60 and 100&#xa0;g of the minced tissue was stored overnight at 4&#xb0;C in 1 x phosphate buffered saline (PBS, Medicado, Cat #09-9400-100). On the next day, the tissue was digested with trypsin (0.25%, Sigma Aldrich, Cat #T4549) and DNase I (0.08 mg/ml; Roche, Cat #10104159001), followed by digestion with collagenase A (1 mg/ml; Roche, Cat #10103586001) and DNase I (0.08 mg/ml, Roche, Cat #10104159001). The cell suspension containing the HBCs was applied to a Percoll gradient (20-40%, Sigma Aldrich, Cat #P4937) and centrifuged unrestrained at 1000&#xa0;g for 30&#xa0;min. At this point, the HBCs appearing as bands between 30 and 35% gradient layers were aspirated and purified by negative selection using Dynabeads (Invitrogen, Cat #11033) coated with antibodies against epithelial growth factor receptor (EGFR, Santa Cruz, Cat #sc-120) and CD10 (Sigma Aldrich, Cat #SAB4700440). After immunopurification, cells were seeded in macrophage medium (MaM, ScienCell, Cat #SC1921) containing 5% FBS (ScienCell, Cat #SC1921), PenStrep (ScienCell, Cat #SC1921) and macrophage growth supplements (ScienCell, Cat #SC1921) at a cell density of 1x10<sup>6</sup> cells/ml. Cells were cultured at 21% oxygen and 37&#xb0;C. Quality control of the isolated HBCs was performed on the fixed cells after 6 days by immunocytochemistry for CD163 (Thermo Fischer Scientific, Cat #MA1-82342), CD90 (Dianova, Cat # DIA100), CD80 (Abcam, Cat #ab86473), CD68 (Dako, Cat #GA613), CD86 (Abcam, Cat #ab270719), CD206 (Novus, Cat #H00004360), CD209 (R&amp;D Systems, Cat #MAB1621), and isotype control (Dako, Cat #X0931) as previously described by Schliefsteiner et&#xa0;al. (<xref ref-type="bibr" rid="B31">31</xref>). Cell culture images were obtained using brightfield microscope with a SC50 Olympus camera and CellSens software.</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Immunohistochemistry</title>
<p>Tissue sections were taken from four different areas of placenta (reaching from chorionic plate to the decidual side and a central region of the placental disk) and fixed overnight in 4% neutral buffered paraformaldehyde solution. After paraffin embedding, tissue sections with a thickness of 5&#x3bc;m were mounted on glass slides. The paraffin was then removed with xylene and rehydrated in an ethanol dilution series. Antigen retrieval was performed using a citrate buffer (Gatt, Cat #403139070) adjusted to pH 6.0. UltraVision LP detection system (Thermo Fischer Scientific, Cat #TL125HL) was used for histochemical immunostaining. Tissue was incubated with Hydrogen Peroxide Block (Thermo Fischer Scientific, Cat #TL125HL) for 15 minutes and washed in TBE buffer (Gatt, Cat #403211370), followed by a 5-minute incubation with Ultra V protein block (Thermo Fischer Scientific, Cat #TL125HL). The primary antibody isotype control (1:200, Dako, Cat #X0931) and CD163 (1:200, Thermo Fischer Scientific, Cat #MA1-82342) were diluted in antibody diluent (Agilent, Dako, Cat #S0809) and incubated overnight at 4&#xb0;C in a humidified chamber. After washing step, primary antibody enhancer (Thermo Fischer Scientific, Cat #TL125HL) was applied for 20 minutes. After another washing step samples were incubated with Large HRP Polymer (Thermo Fischer Scientific, Cat #TL125HL) solution for 30 minutes, followed by intensive washing and incubation with AEC Chromogen Solution (Abcam, Cat #64252) for 10 minutes. The tissue was counterstained with Haematoxylin (Gatt-Koller Cat #401296170) for 1 minute and mounted with embedding medium. Images were acquired using CellSens Standard software and an Olympus BX53 light microscope with an Olympus UC90 camera. Per slide, images of 5-10 different areas were taken and quantified with Qupath software (<xref ref-type="bibr" rid="B49">49</xref>).</p>
</sec>
<sec id="s2_4">
<label>2.4</label>
<title>Fluorescence assisted cell sorting (FACS)</title>
<p>FACS was performed to quantify the cell populations expressing M1 and M2 polarization markers of HBCs. On the fifth day after isolation, cells were harvested using accutase (Thermo Fischer Scientific, Cat #00-4555-56<bold>)</bold> and gentle scraping. Viability and number of cells after scraping was determined using a CASY cell counter model TT (Innovatis, Bielefeld). At least 1x10<sup>5</sup> viable cells per tube were used for the experiment. Cells were resuspended in 3% FCS - HBSS solution for 10&#xa0;min at room temperature to block Fc-receptors and reduce non-specific binding. For surface staining, cells were incubated with a fluorochrome-conjugated antibody in the amount indicated in the <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Table&#xa0;1</bold></xref> for 20 minutes at 4&#xb0;C in the dark. Cells were washed with staining buffer [PBS containing 0.1% BSA (Sigma Aldrich, Cat #A2153) and 2mM EDTA (Thermo Fischer Scientific, Cat #15575020)], centrifuged at 300&#xa0;g for 5 minutes and resuspended in 200 &#xb5;L staining buffer. For detection of surface molecules, a minimum of 10000 live events per sample were counted. In order to identify expression of surface markers, cells were separated by size using forward and size scatter (FSC and SSC, respectively), followed by doublet discrimination. In the next step, cells were discriminated into live and dead cells using the 7-AAD dye (BD Biosciences, Cat #559925) by plotting it against the SSC area. In the fourth step cells were plotted for the respective marker against the SSC area. For staining of intracellular molecules, cells were fixed and permeabilized with BD Cytofix/Cytoperm kit (BD Biosciences, Cat #554714). Staining was performed according to the manufacturer&#x2019;s instructions. A minimum of 10000 events per sample were counted. To investigate the expression of intracellular polarization markers cells were separated by size using forward and size scatter (FSC and SSC, respectively), followed by doublet discrimination and gating against SSC-area and respective marker. The same gating strategy was employed on CTR and PE macrophages. Surface molecules were compensated by individual staining on OneComp eBeadsTM Compensation Beads (Thermo Fischer Scientific, Cat #01-1111-42). Isotype controls corresponding to each fluorochrome in the experiment were used to detect non-specific positive signals. Antibodies used for FACS analysis and their corresponding dilutions are listed in the <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Table&#xa0;1</bold></xref>. Cell sorting was performed using a CytoFLEX flow cytometer (Beckman Coulter, Brea, CA, USA) and analysed with FlowJoTM v10.8 software for gate setting and data analysis.</p>
</sec>
<sec id="s2_5">
<label>2.5</label>
<title>Multiplex ELISA-on-bead Assay</title>
<p>Inflammation 20-Plex Human ProcartaPlex&#x2122; Panel (Invitrogen, Thermo Fischer Scientific, Cat #EPX200-12185-901) was used to quantify the secretion of pro- and anti-inflammatory molecules. Human TIMP Magnetic Luminex Performance Assay 4- Plex Kit (R&amp;D Systems, Cat #LKTM003) was used to analyse TIMP secretion. HBCs were cultured in MaM for 5-6 days before supernatants were collected and centrifuged at 4000 rpm, 4&#xb0;C for 15 minutes. MaM medium processed under the same conditions as the samples served as a blank. Multiplex assays were performed according to the manufacturer&#x2019;s instructions. Cytokines reaching the detection limits were normalized to total protein content in the supernatant using the Pierce BCA kit (Thermo Fischer Scientific, Cat #23225).</p>
</sec>
<sec id="s2_6">
<label>2.6</label>
<title>Enzyme- linked immunosorbent assay (ELISA)</title>
<p>TGF-beta 1 Quantikine ELISA kit for human/mouse/rat/porcine/rabbit (R&amp;D Systems, Cat #DB100B) was used for the detection of TGF-&#x3b2;1. Next, to quantify secretion of IL-8, human IL -8/CXCL8 Quantikine ELISA kit (R&amp;D Systems, Cat #D8000C) was used. Both ELISA kits were performed according to the manufacturers&#x2019; instructions. To quantify the amount of secreted TGF-&#x3b2;1 and IL-8, cells were cultured in MaM for 5-6 days before collection of the supernatants. MaM medium processed under the same conditions as the samples, but without cells served as a blank. Cytokine levels were normalized to the total protein content in the supernatant measured with the Pierce BCA kit (Thermo Fischer Scientific, Cat #23225), in order to account for deviating volume concentrations.</p>
</sec>
<sec id="s2_7">
<label>2.7</label>
<title>Quantitative Real-Time PCR (RT-qPCR)</title>
<p>HBCs were washed twice with ice cold Hanks&#x2019; salt balanced solution (HBSS, Thermo Fischer Scientific, Cat #14175-053) and harvested in 700 &#xb5;L QIazol Lysis Reagent (Quiagen, Cat #79306). Total RNA content was isolated using miRNeasy Mini Kit (Quiagen, Cat #217004). Reverse transcription was performed using 1 &#xb5;g of RNA and Luna Script RT SuperMix Kit (New England BioLabs, Cat #M3010). For qPCR analysis, SYBR Green Luna Universal qPCR Master Mix (New England BioLabs, Cat #M3003) and CFX-384 Touch Real time PCR detection system (Bio-Rad) were used. Expression of target genes was normalized to the following housekeeping genes (<italic>18S</italic>, <italic>RPL30</italic> and <italic>HPRT</italic>) using 2^(<sup>&#x394;&#x394;Ct</sup>) method. Primer sequences used for qPCR analysis are listed in the <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Table&#xa0;2</bold></xref>.</p>
</sec>
<sec id="s2_8">
<label>2.8</label>
<title>Phagocytosis assay measured with FACS</title>
<p>Phagocytosis Assay Kit (Abcam, Cat #ab234053) was used according to the manufacturer&#x2019;s instructions. For detection of phagocytic activity 1 x 10<sup>6</sup> cells/ml were used. On the fifth day post isolation HBCs were treated with zymosan slurry and incubated for 3 hours at 21% oxygen and 37&#xb0;C. After washing steps, cells were detached using accutase (Thermo Fischer Scientific, Cat #00-4555-56) and careful scraping, followed by a washing step with staining buffer containing PBS with 0.1% BSA (Sigma Aldrich, Cat #A2153) and 2mM EDTA (Thermo Fischer Scientific, Cat #15575020). Afterwards measurements were performed in the FITC channel. Untreated cells served as controls. Cells were separated by size using FSC-A and SSC-A, followed by doublet discrimination gating the area and height of FSC. Lastly, the FITC fluorescent signal was determined using histograms. Cell sorting was performed on a CytoFLEX flow cytometer (Beckman Coulter, Brea, CA, USA) using FlowJoTM v10.8software for gate setting and data analysis.</p>
</sec>
<sec id="s2_9">
<label>2.9</label>
<title>Phagocytosis assay with high-content confocal screening microscope</title>
<p>Phagocytosis Assay Kit (Abcam, Cat #ab234053) was used according to the manufacturer&#x2019;s instructions. HBCs were seeded at the density of 0.5 x 10<sup>6</sup> cells/ml in 24-well black/clear bottom plates. 5 &#xb5;L of zymosan slurry was added to the cells and incubated at 21% oxygen and 37&#xb0;C for 3 hours, followed by a washing step. Next, cells were fixed in a plate containing 4% neutral buffered paraformaldehyde solution, followed by an intensive wash step with TBE buffer containing 1x TBE and 0.1% Tween (Thermo Fischer Scientific, Cat #003005). HBCs were incubated with Protein Block (Thermo Fischer Scientific, Cat #TL125HL) for 20 minutes. Cells were then counterstained with CD163 (1:100, Thermo Fischer Scientific, Cat #MA1-82342), diluted to working concentration in Antibody diluent (Agilent, Dako, Cat #S0809) and incubated overnight at 4&#xb0;C. After serial washing steps, the plate was incubated with the secondary antibody Dylight633 (goat versus mouse 1:200, Thermo Fischer Scientific, Cat #35512) for 2&#xa0;h at room temperature. To stain the nuclei, the plate was counterstained with DAPI (1:1000, Sigma Aldrich, Cat #D9542) diluted in antibody diluent for 10&#xa0;min. After intensive washing, 300 &#xb5;L of PBS was added to each well and stored at 4&#xb0;C. Image acquisition was performed using a Nikon microscope with the Zyla sCMON camera. All statistical analysis was carried out on 25 different locations per well using 20x magnification. For better visualization of phagocytosis shown images in the <xref ref-type="fig" rid="f4"><bold>Figures&#xa0;4C&#x2013;E</bold></xref> were taken with 40x magnification. The number of FITC labelled beads was counted within the cells positive for CD163 and DAPI staining using Nis Elements viewer version 5.20.01 software. Cell surface area was measured using the measuring tool provided within the software.</p>
</sec>
<sec id="s2_10">
<label>2.10</label>
<title>Gelatin zymography</title>
<p>HBCs supernatants were collected on the fifth day post isolation. The supernatants were centrifuged at 4000 rpm for 15 minutes at 4&#xb0;C. Total protein concentration was determined using Pierce BCA kit (Thermo Fischer Scientific, Cat #23225) according to the manufacturer&#x2019;s guidelines. A total of 15 &#xb5;g of protein sample was diluted with Tris-Glycine SDS sample buffer (Thermo Fisher Scientific, Cat # LC2676) and loaded onto 10% Tris-Glycine gels containing 0.1% gelatin (Thermo Fisher Scientific, Cat #ZY00105BOX) and separated for 135&#xa0;min at 125&#xa0;V, 35 mA. After electrophoresis, the gels were incubated in 1x Zymogram Renaturating buffer (Thermo Fisher Scientific, Cat #LC2670) at room temperature with gentle agitation. Followed by 30 minutes incubation with 1x Zymogram developing buffer (Thermo Fisher Scientific, Cat #LC2671). Fresh developing buffer was added and the gels were stored overnight at 37&#xb0;C. Next day, gels were stained with Coomassie Brilliant Blue (Sigma Aldrich, Cat #1.15444) for 50 minutes and decolorized in 50% distilled water (Fresenius, Cat #C920928): 40% methanol (Sigma Aldrich, Cat #322415): 10% acetic acid (Roth, Cat #3738.5) solution for 10 minutes. Protease activity appearing as a clear band on the dark background was visualized with the ChemiDoc&#x2122;Touch Imaging System (Bio-Rad). Band densitometry was determined using Image Lab Software Version 6.1 (Bio-Rad).</p>
</sec>
<sec id="s2_11">
<label>2.11</label>
<title>Statistical analysis</title>
<p>SPSS (IBM SPSS Statistics version 26) was used for statistical calculations. Next, graphs were generated using Graph Pad Prism 9.3.1 software (GraphPad Software Inc.). To test normal distribution Shapiro-Wilk test was used. Skewed data were transformed using natural logarithm (ln) before applied to statistical analysis and re-transformed for the graphical presentation. To assess statistical significance of the patient characteristics (<xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref>) one-way ANOVA with Tukey&#x2019;s <italic>post-hoc</italic> test was used. If normality testing failed, Kruskal-Wallis test with Dunn&#x2019;s <italic>post-hoc</italic> test was performed. Next, to compare differences between three groups (CTR; EO-PE and LO-PE) ANCOVA with adjustment for gestational age and Sidak&#x2019;s <italic>post-hoc</italic> test was used. Equal variances of variables were verified by Levene&#xb4;s test. When comparing the effect of HBCs conditioned medium on fpECs without adjustment for gestational age (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;5</bold></xref>) two-way ANOVA with Sidak&#x2019;s <italic>post-hoc</italic> test was used. All values are given as mean &#xb1; S.E.M. p-values &#x2264; 0.05 were considered statistically significant.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title>The number and morphology of HBCs is affected by PE</title>
<p>The characteristics of the study population are shown in <xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref>. Women who developed early (EO, n=8) and late onset (LO, n=6) PE were included in this pilot study. Advanced maternal age, high pre-pregnancy BMI, nulliparity, gestational diabetes, chronic hypertension are some of the risk factors for the development of PE (<xref ref-type="bibr" rid="B1">1</xref>). Women in PE groups were significantly older as those in CTR group and their pre-pregnancy BMI ranged from 19.6 to 25.4 kg/m2. As expected, systolic and diastolic blood pressure levels differed significantly between the CTR and PE groups. Gestational age of EO-PE group was significantly lower than of CTR and LO-PE group. Consequently, early gestational age of the EO-PE group is directly related to placental- and fetal weight, both of which were significantly lower than in CTRs. Since development of the placenta depends on gestational age (<xref ref-type="bibr" rid="B50">50</xref>), we adjusted the (normally distributed) data for that respective factor. We found a significant difference in the levels of sFlt between EO- and LO-PE group, while there were no significant differences between other clinical parameters (PlGF, platelets, uric acid, AST and ALT).</p>
<p>To study polarization, we first examined the distribution and number of HBCs in placental tissue using immunohistochemistry approach. Since HBCs have been shown to be strongly positive for CD163, we stained 5 &#xb5;m serial sections of CTR (n=5), EO-PE (n=6) and LO-PE (n=6) placental tissue, mouse IgG served as a negative control. CD163 is used as a marker used for placenta resident macrophages, and if combined with other markers (e.g. Folate receptor-&#x3b2;, CD206, CD209) is often associated with M2 polarization (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B51">51</xref>). HBCs positive for CD163 were found in the villous stroma, moreover in stem, intermediate and terminal villi of CTR, EO- and LO- PE placentae (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1A</bold></xref>). Furthermore, quantification of CD163-positive cells revealed a significantly decreased number of stained (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1B</bold></xref>) cells per mm<sup>2</sup> in both PE groups, indicating reduced number of HBCs in respective groups. Next, we adjusted the number of isolated HBCs to the wet weight (grams) of placental tissue used for isolation. Consistent with immunohistochemical analysis, we found significantly reduced number of primary LO-PE HBCs. Reduction of HBCs was also observed in the EO-PE group, however, did not reach significance compared to the CTRs (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1C</bold></xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Immunohistochemical assessment of CD163 in placental tissue. <bold>(A)</bold> Representative images of serial sections of CTR (n=5), EO- (n=6) and LO-PE (n=6) are shown. Insert in the top right corner of CTR image depicts negative control stainings (blue). Images were taken at 20x magnification, scale bar represents 50&#xb5;m. <bold>(B)</bold> Quantification of cells positive for CD163 in CTR, EO- and LO-PE group. Cells were quantified by using Quapath software. <bold>(C)</bold> Average yield of HBCs, adjusted to the wet weight (in grams) of minced tissue for each respective isolation, CTR (n=22), EO-PE (n=8), LO-PE (n=6). Data on <bold>(B)</bold> in <bold>(C)</bold> graphs are presented as mean &#xb1; S.E.M, ANCOVA with adjustment for gestational age, followed by Sidak&#x2019;s <italic>post-hoc</italic> test to examine statistical significance, *p &#x2264; 0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-1095879-g001.tif"/>
</fig>
<p><italic>In vitro</italic>, cell morphology of HBCs isolated from CTR, EO- and LO-PE placentae showed substantial differences (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure S1</bold></xref>). Normally, directly after isolation, HBCs are round shaped cells with many vacuoles in the cytosol. Within 48-72 hours after isolation, cells differentiate and develop different shapes. Usually, M2 characterized macrophages exhibit an elongated, spindle-shaped morphology, whereas M1 polarized cells form a round, dendritic cell-like morphology with large filopodia (<xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>). CTR HBCs developed typical M2 features (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;1A</bold></xref>), whereas within isolations of EO- and LO-PE HBCs more of round shaped cells with larger filopodia next to M2 morphologies were found (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figures&#xa0;1B, C).</bold></xref>
</p>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>EO- and LO-PE HBCs are characterized by different expression of polarization markers</title>
<p>Basal expression of surface and intracellular M1 and M2 markers was determined by FACS (<xref ref-type="table" rid="T2"><bold>Tables&#xa0;2</bold></xref> and <xref ref-type="table" rid="T3"><bold>3</bold></xref>) on primary isolated CTR (n=12), EO-PE (n=6) and LO-PE (n=5) HBCs. The gating strategy is shown in <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;2</bold></xref>. FACS analysis revealed distinct expression of M1 and M2 markers in EO- and LO- PE HBCs (<xref ref-type="table" rid="T2"><bold>Table&#xa0;2</bold></xref>). EO-PE HBCs tend to express higher levels of pro-inflammatory CD11b, CD11c, CD40 (p=0.09) and TLR4 (p &#x2264; 0.05), whereas expression of listed markers was similarly distributed between LO-PE and CTR HBCs, except for CD209 (p &#x2264; 0.001). Furthermore, we found significant increase of the major histocompatibility class (MHC) II molecule HLA-DR within the EO-PE group compared to the CTR group (p&#x2264; 0.001). Interestingly, the HLA-DR expression was significantly different between EO- and LO-PE HBCs (p&#x2264; 0.01) as well. Among the M1 markers only expression of CD80 (p=0.05) and TLR1 (p &#x2264; 0.05) were elevated in LO-PE group. Notably, expression of CD80 and TLR1 was elevated in EO-PE group as well, but only by trend. Interestingly, surface expression of TLR2 was reduced in both EO- (p &#x2264; 0.05) and LO-PE group. Next, we investigated the expression levels of CD86. Since CD86 can serve as M1 or M2b marker (<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>), the secretion profile and expression of other markers should be taken into account when interpreting its expression. We found significant induction of the expression of the respective marker in EO-PE HBCs (p &#x2264; 0.05) compared to the CTR (p &#x2264; 0.05) or LO-PE (p &#x2264; 0.05) group. In LO-PE HBCs the expression of CD86 did not differ from the control. In contrast to the increase of pro-inflammatory markers in EO-PE HBCs, a slight decrease in the anti-inflammatory markers CD206 and folate receptor &#x3b2; (FR-&#x3b2;) was observed. Expression pattern of CD206 and FR-&#x3b2; was similar in LO-PE HBCs as well. Expression of CD163 on primary isolated HBCs was evenly distributed between all investigated groups, confirming that CD163 can be used rather as a reliable tissue resident marker (<xref ref-type="fig" rid="f1"><bold>Figures&#xa0;1A, B</bold></xref>) than a direct indicator of M2 phenotype. Next, M2 marker CD209 was suppressed in the LO-PE group (p &#x2264; 0.001). Its expression was only minimally decreased by 10% in EO-PE HBCs group. Interestingly, we found a significant difference in the expression of CD209 between EO- and LO-PE HBCs (p &#x2264; 0.01).</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Percentage of live cells positive for respective surface polarization markers within the CTR (n=12), EO- (n=6) and LO-PE (n=5) groups.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Surface<break/>polarization marker</th>
<th valign="middle" align="center">CTR<break/>(% of live cells)</th>
<th valign="middle" align="center">EO-PE<break/>(% of live cells)</th>
<th valign="middle" align="center">LO-PE<break/>(% of live cells)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">CD11B</td>
<td valign="middle" align="center">22.2 &#xb1; 9.6</td>
<td valign="middle" align="center">38.7 &#xb1; 16.5</td>
<td valign="middle" align="center">28.8 &#xb1; 17.0</td>
</tr>
<tr>
<td valign="middle" align="left">CD11C</td>
<td valign="middle" align="center">45.1 &#xb1; 14.3</td>
<td valign="middle" align="center">69.9 &#xb1; 17.8</td>
<td valign="middle" align="center">51.9 &#xb1; 11.8</td>
</tr>
<tr>
<td valign="middle" align="left">CD40</td>
<td valign="middle" align="center">17.1 &#xb1; 5.9</td>
<td valign="middle" align="center">38.9 &#xb1; 12.6</td>
<td valign="middle" align="center">22.6 &#xb1; 10.9</td>
</tr>
<tr>
<td valign="middle" align="left">CD80</td>
<td valign="middle" align="center">2.9 &#xb1; 1.8</td>
<td valign="middle" align="center">6.5 &#xb1; 3.5</td>
<td valign="middle" align="center">10.5 &#xb1; 8.9</td>
</tr>
<tr>
<td valign="middle" align="left">CD86</td>
<td valign="middle" align="center">25.0 &#xb1; 10.3 *</td>
<td valign="middle" align="center">41.7 &#xb1; 3.6 &#x2021;</td>
<td valign="middle" align="center">21.6 &#xb1; 6.8</td>
</tr>
<tr>
<td valign="middle" align="left">CD163</td>
<td valign="middle" align="center">89.4 &#xb1; 3.9</td>
<td valign="middle" align="center">82.0 &#xb1; 4.5</td>
<td valign="middle" align="center">81.8 &#xb1; 6.8</td>
</tr>
<tr>
<td valign="middle" align="left">CD206</td>
<td valign="middle" align="center">47.6 &#xb1; 9.8</td>
<td valign="middle" align="center">33.5 &#xb1; 6.5</td>
<td valign="middle" align="center">38.2 &#xb1; 13.3</td>
</tr>
<tr>
<td valign="middle" align="left">CD209</td>
<td valign="middle" align="center">53.3 &#xb1; 6.9 &#x2020;&#x2020;&#x2020;</td>
<td valign="middle" align="center">43.7&#xb1; 12.1 &#x2021;&#x2021;</td>
<td valign="middle" align="center">22.1 &#xb1; 5.2</td>
</tr>
<tr>
<td valign="middle" align="left">TLR1</td>
<td valign="middle" align="center">5. 9 &#xb1; 6.2 &#x2020;</td>
<td valign="middle" align="center">9.5 &#xb1; 6.2</td>
<td valign="middle" align="center">18.8 &#xb1; 13.6</td>
</tr>
<tr>
<td valign="middle" align="left">TLR2</td>
<td valign="middle" align="center">6.1 &#xb1; 3.9 *</td>
<td valign="middle" align="center">1.2 &#xb1; 1.5</td>
<td valign="middle" align="center">5.4 &#xb1; 4.5</td>
</tr>
<tr>
<td valign="middle" align="left">TLR4</td>
<td valign="middle" align="center">37.3 &#xb1; 12.3 *</td>
<td valign="middle" align="center">79.7 &#xb1; 19.9</td>
<td valign="middle" align="center">54.2 &#xb1; 18.8</td>
</tr>
<tr>
<td valign="middle" align="left">HLA-DR</td>
<td valign="middle" align="center">33.8 &#xb1; 14.1 ***</td>
<td valign="middle" align="center">77.9 &#xb1; 12.6 &#x2021;&#x2021;</td>
<td valign="middle" align="center">44.3 &#xb1; 18.7</td>
</tr>
<tr>
<td valign="middle" align="left">FR-&#x3b2;</td>
<td valign="middle" align="center">79.2 &#xb1; 10.0</td>
<td valign="middle" align="center">77.6 &#xb1; 20.7</td>
<td valign="middle" align="center">68.4 &#xb1; 15.3</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Data are presented as mean &#xb1; SD. Statistical significance is represented with *p &#x2264; 0.05, ***p &#x2264; 0.001; whereas *CTR vs EO-PE; &#x2020;p &#x2264; 0.05, &#x2020;&#x2020;&#x2020;p &#x2264; 0.001; whereas &#x2020;CTR vs LO-PE; &#x2021; p &#x2264; 0.05, &#x2021;&#x2021;p &#x2264; 0.01; whereas &#x2021;EO-PE vs LO-PE, by ANCOVA with Sidak&#x2019;s post-hoc test and adjustment for gestational age.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Percentage of positive CTR (n=12), EO-PE (n=5) and LO-PE (n=4) HBCs for respective intracellular polarization markers.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Intracellular polarization marker</th>
<th valign="middle" align="center">CTR<break/>(% of positive cells)</th>
<th valign="middle" align="center">EO-PE<break/>(% of positive cells)</th>
<th valign="middle" align="center">LO-PE<break/>(% of positive cells)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">CD68</td>
<td valign="middle" align="center">84.0 &#xb1; 9.8</td>
<td valign="middle" align="center">70.4 &#xb1; 9.1</td>
<td valign="middle" align="center">87.5 &#xb1; 5.4</td>
</tr>
<tr>
<td valign="middle" align="left">IRF4</td>
<td valign="middle" align="center">91.6 &#xb1; 8.0</td>
<td valign="middle" align="center">85.7 &#xb1; 11.8</td>
<td valign="middle" align="center">96.2 &#xb1; 2.0</td>
</tr>
<tr>
<td valign="middle" align="left">IRF5</td>
<td valign="middle" align="center">73.1 &#xb1; 12.8</td>
<td valign="middle" align="center">91.5 &#xb1; 10.8</td>
<td valign="middle" align="center">85.2 &#xb1; 12.0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Data are presented as mean &#xb1; SD. Statistical significance was tested by ANCOVA with Sidak&#x2019;s post-hoc test and adjustment for gestational age.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In addition to the investigation of surface polarization markers, we studied intracellular markers (<xref ref-type="table" rid="T3"><bold>Table&#xa0;3</bold></xref>). Next to the pan-macrophage marker CD68, two important regulators of TLR-Myd88 signaling (<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B57">57</xref>), IRF4 and IRF5 were investigated. Noteworthy, IRF4/IRF5 axis is involved in the initiation control of a specific M1/M2 polarization program. IRF5 as a positive regulator of Myd88 induces the expression of pro-inflammatory genes and establishment of M1 phenotype (<xref ref-type="bibr" rid="B58">58</xref>). Whereas IRF4, as a negative regulator of Myd88, leads to the activation of anti-inflammatory genes and initiation of M2 polarization (<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B59">59</xref>).We found the highest expression of IRF5 in EO-PE group and the lowest in CTRs. Expression of IRF4 the regulator of M2 polarization was evenly distributed between CTR and LO-PE group. Importantly, expression of IRF4 in EO-PE HBCs was reduced. Moreover, balance in favour of IRF5 together with higher expression of other surface M1 markers (<xref ref-type="table" rid="T2"><bold>Table&#xa0;2</bold></xref>) indicates possible phenotypic switch towards M1 polarization of EO-PE HBCs.</p>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>HBC secretion profile of cytokines and adhesion molecules differs in PE</title>
<p>Polarized macrophages are known to secrete specific patterns of cytokines, chemokines, and growth factors, allowing us to characterize polarization states (<xref ref-type="bibr" rid="B60">60</xref>). Using multiplex ELISA-on-bead technology, we determined the secretion profile of cytokines and chemokines secreted by CTR (n=8), EO-PE (n=6) and LO-PE (n=4) HBCs (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2</bold></xref>, <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;3</bold></xref>). Moreover, secretion of IL-8 was determined using ELISA, since its secretion excided the detection limit of the multiplex ELISA (CTR n=10, EO-PE n=5, LO-PE n= 5; <xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2J</bold></xref>). Notably, TGF-&#x3b2;1 was measured with ELISA (CTR n=12, EO-PE n=6, LO-PE n=6, <xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2K</bold></xref>) since the sample preparation requires acidification of the samples for binding of TGF-&#x3b2; epitopes.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Secretion of cytokines and adhesion molecules by CTR (n=8), EO- (n=6) and LO-PE (n=4) HBCs. Multiplex-ELISA-on-beads assay for followed pro-inflammatory and anti-inflammatory cytokines <bold>(A)</bold> IL-6, <bold>(B)</bold> IL-12p-70, <bold>(C)</bold> TNF-&#x3b1;, <bold>(D)</bold> ICAM, <bold>(E)</bold> IL-17a, <bold>(F)</bold> E-selectin, <bold>(G)</bold> IL-4, <bold>(H)</bold> IL-10 and <bold>(I)</bold> IL-13, respectively. Multiplex was performed in duplicates. <bold>(J)</bold> ELISA against IL-8 performed in duplicates (CTR n=10, EO-PE n=5 and LO-PE n=5). <bold>(K)</bold> ELISA assay against TGF-&#x3b2;1 performed in duplicates (CTR n=12, EO-PE n=6 and LO-PE n=6). Secretion of respective cytokines was normalized to the total protein content measured in the cell culture supernatants. Statistical significance was tested using ANCOVA with adjustment for gestational age followed by Sidak&#x2019;s <italic>post-hoc</italic> test. *p &#x2264; 0.05, **p &#x2264;0.01.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-1095879-g002.tif"/>
</fig>
<p>Secretion profile of EO- and LO-PE HBCs differs from the CTR group. First, among pro-inflammatory cytokines, we discovered a trend of an increased secretion of IL-6, IL-12p70 and P-Selectin by EO-PE HBCs (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2A, B</bold></xref>; <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;3A</bold></xref>). Contrary, to the EO-PE HBCs where secretion of TNF-&#x3b1; was unchanged, LO-PE released higher amounts of TNF-&#x3b1; as CTRs or EO-PE HBCs (p &#x2264; 0.05) (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2C</bold></xref>). LO-PE HBCs secreted higher amounts of ICAM, but only by trend (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2D</bold></xref>). Moreover, both PE groups secreted less IL-17a compared to CTRs (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2E</bold></xref>). Although, release of E-Selectin was higher in both PE groups, we did not find any differences in the production of other pro-inflammatory cytokines, such as: IL-1&#x3b1;, IL-1 &#x3b2;, CCL-3, CCL-4, IFN- &#x3b1;, and IFN-&#x3b3; between investigated groups (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2F</bold></xref>, <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figures&#xa0;3B&#x2013;H</bold></xref>). A decrease of IL-8, measured by ELISA was detected in LO-PE HBC group, whereas unchanged between CTR HBCs and EO-PE group. Interestingly, we found a significant difference in the release of IL-8 between EO- and LO-PE HBCs (p &#x2264; 0.05) (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2J</bold></xref>).</p>
<p>Next, we examined the secretion of anti-inflammatory cytokines namely, IL-4, IL-10, IL-13, and TGF-&#x3b2;1, which serve as important drivers of M2 polarization (<xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B61">61</xref>). We did not find any differences in the secretion of IL-13; however, secretion of IL-4 and IL-10 was increased, but only by trend in EO-PE HBCs. LO-PE HBCs secreted significantly higher levels of IL-4 (p &#x2264; 0.05) and IL-13 (p &#x2264; 0.05) compared to CTR HBCs (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2G&#x2013;I</bold></xref>). Interestingly, both PE groups released significantly higher amounts of anti-inflammatory TGF-&#x3b2;1, which was even more pronounced in the LO-PE group (p &#x2264; 0.01) (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2K</bold></xref>).</p>
<p>Noteworthy, some of the secreted pro-inflammatory cytokines are not reliable identifiers of a specific phenotype, since they are expressed by both M1 and M2 macrophages. E.g. IL-6 is a pro-inflammatory cytokine produced by both M1- and M2a-polarized macrophages (<xref ref-type="bibr" rid="B62">62</xref>). In addition, secretion of ICAM is mediated by NF-&#x3ba;B, but can serve as both an M1 and M2 cytokine due to its pro-angiogenic nature (<xref ref-type="bibr" rid="B63">63</xref>). The observed changes in the secretion profile indicate a switch in the phenotype and possible protective mechanisms of PE HBCs in an attempt to reduce the extent of inflammation by increasing the production of anti-inflammatory cytokines.</p>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Preeclampsia triggers transcriptional changes of HBC-genes involved in inflammation</title>
<p>Macrophages are capable of responding to the local stimuli and acquiring different phenotypes and functions to meet changing physiological needs (<xref ref-type="bibr" rid="B64">64</xref>). Next, we examined transcriptional changes in HBCs that may be triggered by PE. Basal gene expression of CTR (n=12), EO- (n=5) and LO-PE (n=5) HBCs was determined on the fifth day after isolation. We analysed selected genes associated with phenotype and functionality of macrophages undergoing inflammation (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3</bold></xref>). Dynamic changes in gene expression were observed between the PE subgroups EO and LO. First, we found -as expected - an upregulation of <italic>NFKB1</italic> in both EO- and LO-PE groups (p &#x2264; 0.05) (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3A</bold></xref>). Among the inflammatory pathways involved in M1 polarization, NF-&#x3ba;B plays an important role and regulates the expression of pro-inflammatory genes such as cytokines, adhesion molecules and growth factors (<xref ref-type="bibr" rid="B65">65</xref>). Next, the expression of <italic>HIF1</italic>, another M1-associated gene was upregulated in the LO-PE group (p &#x2264; 0.05), whereas its expression was surprisingly decreased in EO-PE group (p &#x2264; 0.05) (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;4</bold></xref>). In line with the increased secretion of <italic>ICAM</italic> (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2H</bold></xref>), mRNA of the respective gene was upregulated in the both PE groups (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;4</bold></xref>). In contrast to the expression of <italic>ICAM, VCAM</italic> was downregulated in EO-PE, whereas in LO-PE group remained on the level of CTRs (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;4</bold></xref>). Consistent with secretion of IL-8 (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2J</bold></xref>), higher fold change of <italic>IL8</italic> was detected in CTR group (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;4</bold></xref>). The expression of <italic>TGFB1</italic>, which acts as important M2 inducer (<xref ref-type="bibr" rid="B66">66</xref>), was significantly elevated in both, EO- and LO-PE HBCs (p &#x2264; 0.05) (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3B</bold></xref>). Although, the differences in the secretion of CCL-4 (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;3H</bold></xref>) were not noticeable, higher expression was detected in the CTR group by RT-qPCR. In contrast to the secretion profile of IL -6 and IL -10, which was higher in the PE group (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2A, H</bold></xref>), qPCR analysis revealed downregulation of respective cytokines in the EO- and LO-PE groups (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;4</bold></xref>), possibly due to the tight post-transcriptional gene regulation of these cytokines in particular (<xref ref-type="bibr" rid="B67">67</xref>). As polarized macrophages metabolise L-arginine differently, M2 <italic>via</italic> arginase-1 and M1 macrophages <italic>via</italic> nitric oxide synthase (iNOS) (<xref ref-type="bibr" rid="B68">68</xref>), we looked at expression of <italic>ARG1</italic> gene, encoding arginase-1, and <italic>NOS2</italic>, encoding iNOS (<xref ref-type="bibr" rid="B68">68</xref>). Interestingly, <italic>ARG1</italic> expression was increased in both PE groups (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3C</bold></xref>). However, expression of <italic>NOS2</italic> was strongly upregulated in EO-PE (p &#x2264; 0.05); whereas expression of the respective gene in LO-PE HBCs was even lower as in CTR HBCs (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3D</bold></xref>). In addition to the metabolism of L-arginine, regulation of reactive oxygen species (ROS), represents an important link between M1 and M2 polarization (<xref ref-type="bibr" rid="B69">69</xref>). M1 macrophages produce higher amounts of ROS and consequently downregulate antioxidant enzymes such as <italic>CAT</italic> encoding catalase, or <italic>SOD</italic> encoding superoxide dismutase (<xref ref-type="bibr" rid="B70">70</xref>), whereas, M2 macrophages are thought to produce lower levels of ROS and express higher levels of <italic>CAT</italic> or <italic>SOD</italic> (<xref ref-type="bibr" rid="B71">71</xref>). The expression of the genes <italic>CAT</italic> and <italic>SOD</italic>, was significantly attenuated in both, EO- and LO-PE groups (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3E, F</bold></xref>). Next in respect to observed TGF-&#x3b2;1 differences, we looked at the expression of genes involved in tissue remodeling and adhesion. Importantly, we found upregulation of <italic>MMP</italic>9 in both PE groups (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3G</bold></xref>). The expression of other genes involved in tissue remodeling (<italic>MMP2, MMP12, TIMP1, TIMP2</italic>), did not differ between groups (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;4</bold></xref>). Adhesion molecules, such as <italic>CDH2</italic> has been downregulated in both EO-PE (p &#x2264; 0.05) and LO-PE HBCs (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3H</bold></xref>). Similarly, as <italic>CDH2</italic> we identified reduced expression of <italic>CDH5</italic> in both, EO- and LO- PE HBCs (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3I</bold></xref>).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Preeclampsia alters inflammatory related gene expression in HBCs. <bold>(A)</bold> Total RNA of cultivated HBCs was harvested on the fifth day post isolation and analysed by RT-qPCR. <bold>(A)</bold> <italic>NFKB1</italic>, <bold>(B)</bold> <italic>TGFB1</italic>, <bold>(C)</bold> <italic>ARG1</italic>, <bold>(D)</bold> <italic>NOS2</italic>, <bold>(E)</bold> <italic>CAT</italic>, <bold>(F)</bold> <italic>SOD</italic>, <bold>(G)</bold> <italic>MMP9</italic>, <bold>(H)</bold> <italic>CDH2</italic>, <bold>(I)</bold> <italic>CDH5</italic>. In total 12 CTR, 5 EO-PE and 5 LO-PE HBCs isolations in three technical replicates were used. Expression of target genes was normalized to the following housekeeping genes (<italic>18S</italic>, <italic>RPL30</italic> and <italic>HPRT1</italic>) using 2<sup>&#x394;&#x394;Ct</sup> method. Statistical significance was tested using ANCOVA with adjustment for gestational age followed by Sidak&#x2019;s <italic>post-hoc</italic> test. *p &#x2264; 0.05 and **p &#x2264; 0.01.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-1095879-g003.tif"/>
</fig>
<p>In the healthy placenta, HBCs are often found in close proximity to feto-placental endothelial cells (fpEC), and M2 macrophages have the ability to regulate placental angiogenesis by secretion of pro-angiogenic factors (<xref ref-type="bibr" rid="B26">26</xref>). To gain insight into their role in angiogenesis, HBCs were examined for the expression of <italic>FLT, VEGFA, KDR</italic>, and <italic>EGFR</italic>; which were all downregulated in EO- and LO-PE group (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;4</bold></xref>).</p>
<p>Furthermore, EO-PE and CTR fpECs were treated with conditioned medium (CM) collected from CTR and EO-PE HBCs. In order to further investigate the influence of HBCs on the fpEC, metabolic activity of fpECs using the MTS assay (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;5A</bold></xref>) and the proliferation of the fpEC by incorporation of BrDU (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;5B</bold></xref>) were measured. CM of CTR HBCs increased the NAD(P)H dehydrogenase activity of CTR fpEC, whereas PE CM had no effect on the activity of PE fpEC (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;5A</bold></xref>). A similar effect was observed when the proliferation of CTR fpEC was measured (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;5B</bold></xref>).</p>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>Phagocytosis of HBCs is altered in PE</title>
<p>Macrophages, as professional phagocytes eliminate pathogens and apoptotic cells. The elimination of apoptotic cells plays an important regulatory role regarding the reduction of the inflammatory burden (<xref ref-type="bibr" rid="B72">72</xref>). Phagocytosis was measured and visualised using two different approaches. First, it was assessed by FACS (CTR n=10, EO-PE n=5, LO-PE n=5), where median fluorescence intensity (MFI) was used to quantify the phagocytic activity. PE HBC showed significantly higher phagocytic activity (p &#x2264; 0.01) than CTRs (<xref ref-type="fig" rid="f4"><bold>Figures&#xa0;4A, B</bold></xref>). Second, we analysed phagocytic activity using HCS (<xref ref-type="fig" rid="f4"><bold>Figures&#xa0;4C&#x2013;E</bold></xref>). For better visualisation cells were stained with HBCs tissue resident marker CD163. Analysis of CTR (n=7) and PE (n=5, EO n=3, LO n=2) confirmed higher (though not significant) phagocytosis of PE HBCs (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4F</bold></xref>). Furthermore, visualisation of phagocytosis allowed us to analyse morphology of the cells, calculating cell size - surface area (&#xb5;M<sup>2</sup>), which was lower in EO- and LO-PE groups, when compared to the surface area (&#xb5;M<sup>2</sup>) of CTRs (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;6</bold></xref>) confirming <italic>in vitro</italic> observations of smaller round cell morphologies of PE HBC (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figures&#xa0;1A&#x2013;C</bold></xref>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>PE HBCs possess a higher phagocytic capacity. <bold>(A)</bold> Gating strategy cells for the measurement of phagocytosis. Cells were separated by size using forward and size scatter (FSC and SSC, respectively), followed by doublet discrimination and gating against SSC-area and FITC -A fluorescent signal. Histograms of one representative experiment are shown, in total 10 CTR, 5 EO-PE and 5 LO-PE HBCs were used. <bold>(B)</bold> Quantification of median fluorescence intensity (MFI) of phagocytosis measured with FACS. <bold>(C)</bold> Visualization of phagocytosis with high content screening microscopy (HCS). HBCs were treated with zymosan beads (green) and co-stained with CD163 (red), DAPI was used to stain nuclei. Representative images of individual experiments are shown. To visualize phagocytosis CTR (<bold>C</bold>, n=7), EO-PE (<bold>D</bold>, n=3) and LO-PE (<bold>E</bold>, n=2) isolations were used. Scale bar represents 20&#xb5;M. <bold>(F)</bold> Quantification of the phagocytosis measured with high content screening. Analysis was carried out with NisViewer Software, analyzing the number of beads within the CD163 positive HBC cell. All data in <bold>(B, F)</bold> are presented as mean &#xb1; S.E.M, ANCOVA with adjustment for gestational age with Sidak&#x2019;s <italic>post-hoc</italic> test was used for to test statistical significance. *p &#x2264; 0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-1095879-g004.tif"/>
</fig>
</sec>
<sec id="s3_6">
<label>3.6</label>
<title>PE attenuates MMP-9 activity of HBCs</title>
<p>In a normal placenta M2-polarized HBCs contribute to tissue remodeling and repair (<xref ref-type="bibr" rid="B73">73</xref>). To confirm strong upregulation of <italic>MMP9</italic> (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3G</bold></xref>), we additionally performed gelatin zymography to assess the activity of MMP-2 and MMP-9 (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5A</bold></xref>). As shown with <italic>MMP2</italic> mRNA expression (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;4</bold></xref>), detectable MMP-2 activity (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5A</bold></xref>) did not differ between studied groups (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5B</bold></xref>). In line with upregulation of <italic>MMP9</italic>, EO-PE HBCs displayed significantly (p &#x2264; 0.05) higher MMP-9 activity as CTR. LO-PE HBCs MMP-9 activity was increased, but only by trend (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5C</bold></xref>).</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Gelatin zymography demonstrating gelatinolytic activity of HBCs. <bold>(A)</bold> A representative zymogram gel showing MMP-9 and MMP-2 activity of CTR (n=5), EO- (n=4) and LO-PE (n=5) HBCs. Activity was examined in the supernatants collected from CTR and PE HBCs on the 5th day post isolation. In total 15&#xb5;g of protein measured in supernatants were loaded onto gelatin gels, respectively. To generate the comparable gelatinolytic bands, gelatin zymography was repeated twice. White bands of gelatinase activity observed at 92 and 82kDa are pro- and active form of MMP-9. Moreover, white bands at the size of 72 and 62kDa represents pro- and active form of MMP-2. Quantification of total (pro and active) form of MMP-9 <bold>(B)</bold> and MMP-2 <bold>(C)</bold> was performed as densitometric analysis of respective bands. <bold>(D)</bold> TIMP-1, TIMP-2, TIMP-3 and TIMP-4 levels measured in the cell culture supernatants using multiplex assay. In total CTR (n=10), EO- (n=4) and LO-PE (n=3) HBCs were used in technical duplicates. Secretion of respective TIMPs was normalized to the total protein content measured in the cell culture supernatants. <bold>(E)</bold> mRNA ratio between <italic>MMP2</italic> and <italic>TIMP1</italic> and <italic>TIMP2</italic>. <bold>(F)</bold> mRNA ratio between <italic>MMP9</italic> and <italic>TIMP1</italic> and <italic>TIMP2</italic>. mRNA ratio was calculated from the -ddCT values normalized to the corresponding housekeeping genes (<italic>18S</italic>, <italic>RPL30</italic> and <italic>HRPT1</italic>). The results are showed as a mean &#xb1; S.E.M of technical triplicates. Statistical significance was assessed using ANCOVA with adjustment for gestational age followed by Sidak&#x2019;s <italic>post-hoc</italic> test. *p &#x2264; 0.05. **p &#x2264; 0.01.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-1095879-g005.tif"/>
</fig>
<p>Expression and production of MMPs are usually tightly regulated within the complex network of their four different tissue inhibitors of metalloproteinases 1-4 (TIMP). HBCs secretion of TIMP- (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B75">75</xref>) was assessed using a multiplex ELISA-on-bead assay (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5D</bold></xref>). Production of TIMP-1, TIMP-2, TIMP-3 was unchanged in EO-PE group, we noticed a decreased production of TIMP-4 in the respective group. Furthermore, LO-PE HBCs secretion of TIMP-1 was significantly decreased, followed by trend in the reduced production of TIMP-2. Interestingly, release of TIMP-3 in LO-PE group was similar as in CTR. LO-PE HBCs production of TIMP-4 was elevated, but only by trend. To further explore the gelatinolytic activity of HBCs, the ratio between mRNA expression of <italic>MMP2/TIMP1</italic>, <italic>MMP2/TIMP2</italic>, <italic>MMP9/TIMP1</italic>, and <italic>MMP9/TIMP2</italic> was calculated. Normally, TIMPs regulate inhibition of MMPs by binding in 1:1 reversible complex with the MMPs (<xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B77">77</xref>). The shift in MMP/TIMP balance in favor of MMPs reflects as increased extracellular matrix (ECM) proteolysis, or if in favor of TIMP as decreased proteolysis and protection of the ECM (<xref ref-type="bibr" rid="B78">78</xref>&#x2013;<xref ref-type="bibr" rid="B80">80</xref>). In CTR, EO- and LO- PE HBCs the ratio between <italic>MMP2</italic> and <italic>TIMP1</italic> or <italic>TIMP2</italic> (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5E</bold></xref>) stayed unchanged. Similar <italic>MMP9/TIMP1</italic> ratio of investigated groups, was favoring the gelatinolytic activity, indicating that MMP-9 is the main gelatinase produced by HBCs. However, significant differences were demonstrated in <italic>MMP-9/TIMP-2</italic> of EO- and LO-PE HBCs, confirming higher gelatinolytic activity shown with gelatin zymography (<xref ref-type="fig" rid="f5"><bold>Figures&#xa0;5A, C, F</bold></xref>).</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Different polarization patterns of CTR, EO - and LO-PE HBCs. HBCs isolated from CTR placenta develop a specific placental phenotype and express both M1 and M2 polarization markers. In CTR placenta, their M2 nature is reflected by increased expression of <italic>ARG1</italic>, <italic>CAT</italic>, and <italic>SOD</italic>, where HBCs promote tissue repair, angiogenesis, and homeostasis. Our results suggest that EO-PE HBCs develop an M2 phenotype that is strongly shifted toward M1 polarization. Their M2 phenotype is reflected in the upregulation of <italic>ARG1</italic>, secretion of TGF-&#x3b2;, and tissue remodeling function, whereas features of M1 polarization are seen in the increased expression of TLR4, HLA-DR, IRF5, and <italic>NOS2</italic>. In contrast, LO-PE HBCs tend to develop a phagocytic CD209<sup>low</sup> M2 phenotype with increased production of IL-4, IL-13, and TGF-&#x3b2;. However, the higher expression of TLR1 and increased production of TNF-&#x3b1; indicate a specific pro-inflammatory pattern that differs from the typical M2 polarization. The figure was generated using BioRender. Differences that were significant different between the groups studied are printed in bold.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-1095879-g006.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>Hofbauer cells, play a pivotal but also a diverse role in placental physiology by maintaining tissue homeostasis and the tolerogenic environment (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B81">81</xref>). HBCs plasticity is well characterized by an unique phenotype expressing both, M2 and M1 polarization markers (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>). Preeclampsia is an inflammatory condition, accompanied by activation of both the innate and adaptive immune system. These alterations may directly influence the phenotype of HBCs and contribute to placental dysfunction (<xref ref-type="bibr" rid="B82">82</xref>). Due to the presumed distinct pathophysiological origins of EO- and LO-PE and the resulting different inflammatory burden within the PE placenta (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B83">83</xref>), we aimed to determine the phenotypic and functional alterations between different HBCs. One of the more significant findings to emerge from this study is that both, EO- and LO-PE HBCs maintain a profound anti-inflammatory phenotype in the human placenta. In addition to HBCs general adaptive response to inflammatory stimuli, EO-PE HBCs cope differently with signals from their microenvironment.</p>
<p>The EO-PE placenta has been linked to placental malperfusion (<xref ref-type="bibr" rid="B84">84</xref>), leading to oxygen deficiency, increased inflammation and oxidative stress which all together deteriorate the mechanisms of placentation early in pregnancy. In contrast, LO-PE placenta has been linked to changes of systemic blood pressure in the mother leading to maternal endothelial dysfunction and oxidative stress, resulting in placental dysfunction (<xref ref-type="bibr" rid="B85">85</xref>, <xref ref-type="bibr" rid="B86">86</xref>). Consequently, both subtypes of PE are characterized by excessive inflammation caused by oxidative stress and a hypoxic microenvironment, which affects the appearance and phenotypic composition of immune cells, particularly macrophages (<xref ref-type="bibr" rid="B87">87</xref>). To investigate whether the number of HBCs differs between CTR and PE placenta, we first quantified the cells <italic>in situ</italic> using specific markers for tissue-resident macrophages. In agreement, with the findings of Tang et&#xa0;al., where they investigated CD163 positive HBCs in PE placentae (<xref ref-type="bibr" rid="B51">51</xref>), we found a decreased number of CD163 - positive macrophages in both EO- and LO-PE placentae. Similarly, Yang et&#xa0;al. observed a significantly reduced number of CD14-positive HBCs in PE (<xref ref-type="bibr" rid="B87">87</xref>). In addition, Broekhuizen et&#xa0;al., used combined staining for CD68 and CD163 and observed a significant decrease in double-positive HBCs in EO-PE, whereas the number of double-positive HBCs in LO-PE remained unchanged (<xref ref-type="bibr" rid="B18">18</xref>). We verified our immunohistochemical findings by analyzing the yield of primary isolated HBCs <italic>in vitro</italic>. Similar to <italic>in situ</italic>, we obtained a decreased number of primary HBCs isolated from EO- and LO-PE placental tissues. As PE placenta is characterized by an increased number of apoptotic trophoblasts (<xref ref-type="bibr" rid="B88">88</xref>, <xref ref-type="bibr" rid="B89">89</xref>), it is likely that HBCs may undergo a similar apoptosis cascade, leading to a decreased number of vital HBCs in culture. According to our results, PE may exacerbate the participation of initial stages of apoptosis in placental tissue which in turn leads to a reduced anti-inflammatory and immunoregulatory capability of remaining HBCs.</p>
<p>Macrophage polarization is a complex process controlled by several factors and mechanisms (<xref ref-type="bibr" rid="B90">90</xref>). It is noteworthy that a subpopulation identified with the same markers may have different functions in different tissues and pathologies, adding to the complexity of defining phenotypes (<xref ref-type="bibr" rid="B27">27</xref>). At baseline, HBCs express M1 and M2 polarization markers (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>). Moreover, HBCs retain alternative M2 polarization in inflammatory complications such as in gestational diabetes mellitus (<xref ref-type="bibr" rid="B31">31</xref>), chorioamnionitis (<xref ref-type="bibr" rid="B91">91</xref>), or upon <italic>in vitro</italic> stimulation (<xref ref-type="bibr" rid="B30">30</xref>). Contrary to expectations, we observed differences in the expression pattern of polarization markers between EO- and LO-PE HBCs. In EO- HBC markers involved in M1 polarization such as TLR4, HLA-DR, CD40, CD80 and CD86 were upregulated, suggesting M1 phenotype. In contrast, in LO-PE HBCs the expression of before mentioned markers was either reduced or similar to CTRs. The anti-inflammatory phenotype of LO-PE HBCs is strongly underpinned by high expression of IRF4, which exerts important function in controlling local cytokine milieu thereby polarization (<xref ref-type="bibr" rid="B92">92</xref>). TLR signaling has been proposed as an important link between activation of innate immune system and PE, known to modulate the inflammatory responses (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B93">93</xref>). Interestingly, Young et&#xa0;al. demonstrated the maintenance of the M2 phenotype of HBCs despite pro-inflammatory treatment and upregulation of TLR4 and increased secretion of pro-inflammatory cytokines (IL-6, IL-8) (<xref ref-type="bibr" rid="B37">37</xref>). We demonstrated an upregulation of TLR4 and its downstream mediators <italic>NFKB1</italic> and TNF-&#x3b1; in EO-PE, implying they give up M2 polarization and a shift towards M1. A change of phenotype toward M1 polarization is also suggested by increased expression of IRF5 and <italic>NOS2</italic>. IRF4 and IRF5, both regulators of the Myd88 pathway are crucial for the expression of M1/M2 genes (<xref ref-type="bibr" rid="B94">94</xref>). In particular, IRF5 regulates the expression of pro-inflammatory factors such as: TNF-&#x3b1;, IL-6, IL-12p70, CD86 (<xref ref-type="bibr" rid="B58">58</xref>). IRF4, on the other hand, is known to compete with IRF5 for interaction with Myd88 to activate the M2 program (<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B92">92</xref>). Its expression has been shown to be induced by anti-inflammatory IL-4 (<xref ref-type="bibr" rid="B92">92</xref>, <xref ref-type="bibr" rid="B95">95</xref>). Interestingly, EO-PE HBCs, although favoring IRF5 activation, express IRF4 and consequently secrete both pro- and anti-inflammatory cytokines. A dysbalance of intracellular IRF4 and IRF5 regulating factors may control different phenotypes and the associated contributions to tissue inflammation.</p>
<p>It has been reported that in PE placentae CD163 and FR&#x2013;&#x3b2;, expression is decreased (<xref ref-type="bibr" rid="B51">51</xref>). Although a reduction of CD163 on tissue levels could be confirmed, no differences of CD163 and FR-&#x3b2; expression on the primary isolated HBCs were detected. This inconsistency can be explained because CD163 is used as a tissue-resident marker for placental macrophages rather than only as an M2 marker. Among anti-inflammatory M2 markers, CD209 serves as one of the major M2 markers, moreover, CD209-positive HBCs have been shown to produce IL -10 an immunosuppressive cytokine one of the drivers of immunoregulatory M2 polarization (<xref ref-type="bibr" rid="B96">96</xref>). Our results suggest differential expression patterns of CD209 between EO- and LO-PE HBCs. Interestingly, the expression of CD209 was unchanged in CTRs and in the EO-PE group, whereas it was significantly reduced in the LO-PE group. In line, LO-PE HBCs tend to secrete lower levels of IL-10 supporting the notion that this polarization pattern favors regulatory properties of these cells. Yang et&#xa0;al. also reported lower numbers of CD209-positive HBCs in PE placental tissues, but they did not distinguish between onsets of PE (<xref ref-type="bibr" rid="B96">96</xref>)</p>
<p>Cytokines are important coordinators that likely promote phenotypic and functional changes of immune cells in inflammation (<xref ref-type="bibr" rid="B90">90</xref>, <xref ref-type="bibr" rid="B97">97</xref>). We have shown that both, EO- and LO-PE HBCs produce different regulators of M2 polarization: IL-4, IL-10, IL-13 and TGF-&#x3b2;. Interestingly, whereas in EO-PE an increased production of TGF-&#x3b2; and IL-10 was observed, LO-PE HBCs secreted higher amounts of IL-4, IL-13, and TGF-&#x3b2;. IL-10 and IL-4, have been recognized as inducers of <italic>ARG1</italic>, which represents a hallmark of M2 polarization (<xref ref-type="bibr" rid="B97">97</xref>&#x2013;<xref ref-type="bibr" rid="B100">100</xref>) IL-10 is a cytokine produced mainly by M2 macrophages (<xref ref-type="bibr" rid="B58">58</xref>) and its anti-inflammatory effect has been demonstrated by reduced production of pro-inflammatory cytokines such as TNF-&#x3b1;, IL-6, and IL-12 (<xref ref-type="bibr" rid="B101">101</xref>, <xref ref-type="bibr" rid="B102">102</xref>). Moreover, although pro-inflammatory M1 marker - IRF5 has been shown to inhibit transcription of IL-10 and TGF-&#x3b2; (<xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B103">103</xref>), this regulation may be impaired in EO-PE, where basal secretion of IL-10 and TGF-&#x3b2; levels were increased. Enhanced expression of M1 polarization markers, upregulation of both M1 <italic>NOS2</italic> and M2 <italic>ARG1</italic>, accompanied by secretion of anti-inflammatory cytokines, indicate a development of a specific M1 and M2 phenotype of EO-PE HBCs. On the other hand, LO-PE HBCs downregulate <italic>NOS2</italic> and express <italic>ARG1</italic> at the same level as CTRs HBCs, suggesting their anti-inflammatory phenotype.</p>
<p>Phenotypic plasticity enables macrophages to perform a variety of functions required for maintenance of homeostasis and rapid termination of inflammation in their microenvironment (<xref ref-type="bibr" rid="B66">66</xref>). The resolution of acute inflammation is a well-orchestrated synergistic process and can be divided into three phases on the way back to cell homeostasis. First, inflammation is downregulated by the temporal switching of secreted lipid mediators, then the clearance of debris and apoptotic cells by phagocytically active macrophages, and finally, tissue repair and angiogenesis are stimulated by the pro-resolving phenotype of macrophages (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B104">104</xref>). We demonstrated a higher phagocytic capacity of EO- and LO-PE compared to normal HBCs, with concomitantly significantly higher levels of TGF-&#x3b2; produced by both groups. Interestingly, TGF-&#x3b2; in monocytes and macrophages is known for its role in maintaining the resolution of inflammation by increasing phagocytosis and restoring tissue integrity (<xref ref-type="bibr" rid="B105">105</xref>&#x2013;<xref ref-type="bibr" rid="B107">107</xref>). The increased phagocytosis and production of anti-inflammatory cytokines (<xref ref-type="bibr" rid="B90">90</xref>) may indicate one of the regulatory mechanisms that determine M2 phenotype of EO- and LO-PE HBCs by preventing a direct switch to M1 polarization.</p>
<p>Following clearance of cell-debris, M2 macrophages initiate events that are critical for tissue repair. These include the production of extracellular matrix (ECM), MMPs and the promotion of angiogenesis (<xref ref-type="bibr" rid="B108">108</xref>). Furthermore, MMPs make an important contribution to ECM repair (<xref ref-type="bibr" rid="B108">108</xref>), and macrophages require active MMP-9 for migration during an inflammatory response (<xref ref-type="bibr" rid="B109">109</xref>). TGF-&#x3b2; acts as a regulator of ECM production, reflecting its role in the tissue remodeling (<xref ref-type="bibr" rid="B110">110</xref>). We have shown compared to normal HBCs that both EO- and LO-PE HBCs secrete higher levels of MMP-9 and TGF-&#x3b2;. Interestingly, one of the many functions of MMP-9 is also to activate the inactive form of TGF-&#x3b2; (<xref ref-type="bibr" rid="B111">111</xref>), suggesting a possible mechanism driving polarization toward M2. MMP-9 is regulated by the expression of TIMPs, which has been shown to have pro-angiogenic features and is unique to M2 macrophages (<xref ref-type="bibr" rid="B112">112</xref>). Although the MMP9/TIMP2 ratio of EO- and LO-PE HBCs favors M2 polarization, we have shown that EO-PE HBCs were unable to stimulate proliferation of endothelial cells. Ability to enhance endothelial proliferation and consequently angiogenesis is one of the traits of M2 macrophages in the process of resolution of inflammation (<xref ref-type="bibr" rid="B104">104</xref>). The unsuccessful activation of proliferation of endothelial cells reveals another aspect of the pro-inflammatory M1 signature of EO-PE HBCs. It is more likely that they contribute to endothelial dysfunction instead of positive pro-angiogenic endothelial activation, but further investigation is needed.</p>
<p>Knowledge about the function of macrophages in PE is still insufficient. Our study focused on the <italic>in vitro</italic> polarization and functionality of EO- and LO-PE HBCs. Our results suggest that EO-PE HBCs develop a strong M1 signature, but despite the M1 features and PE inflammatory microenvironment, they still attempt to resolve inflammation by upregulating M2 anti-inflammatory factors and functions. Based on the fact that the expression of CD209 in EO-PE HBCs is at basal levels as in CTR HBCs, and expression of CD86 and secretion of TGF-&#x3b2; are increased, they might develop an immunoregulatory M2b and a tissue remodeling M2a phenotype with features of M1 polarization based on the increased expression of TLR4, HLA-DR, and IRF5. In contrast, LO-PE HBCs tend to develop a phagocytic M2 phenotype with increased production of IL-4, IL-13, and TGF-&#x3b2;. However, the higher expression of TLR1, TLR4, and CD80 and increased production of TNF-&#x3b1; indicate a specific pro-inflammatory pattern distinct from typical M2 polarization (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6</bold></xref>). Given the strength of our study, namely the use of a large number of clinically well-characterized samples from EO- and LO-PE placenta, there are some apparent limitations. First, macrophage polarization is a dynamic process, and therefore the choice of polarization markers included may vary among investigators. Because characterization of macrophage phenotype using polarization markers and cytokine release is rather descriptive, we chose to use functional assays to determine the relevant physiological functions of macrophages in addition to their phenotype. Second, primary HBCs might develop a different polarization pattern than <italic>in vivo</italic> because of the sensitivity of primary HBCs to the <italic>in vitro</italic> environment. However, we and others have shown that Hofbauer cells have a very stable phenotype <italic>in vitro</italic> that is difficult to alter and correlates with the phenotype in tissue <italic>in vivo</italic> (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B37">37</xref>).</p>
<p>In conclusion, to the best of our knowledge, this is the first study to show a pivotal difference of the polarization pattern between EO - and LO-PE HBCs <italic>in vitro</italic>. We demonstrated that the inflammatory environment of PE causes the phenotypic changes observed between early and late PE HBCs. The changes in polarization patterns indicate different etiologies of PE, as EO-PE is associated with inflammation on the placental side, whereas LO-PE results from a maternal inflammatory response. Furthermore, since placental immune cells responds differently to the source of inflammation, PE could be identified as different entities with a common phenotype rather than a single disorder.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Material</bold></xref>. Further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving human participants were reviewed and approved by Institutional ethics committee of the Medical University of Graz (29-319 ex 16/17). The patients/participants provided their written informed consent to participate in this study.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>MHM and CW conceived the study and designed the experiments. MHM performed the experiments and analysed the data. Reviewing and editing was done by CS and HF. MHM and CW wrote the original draft manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>MHM is supported through the PhD program Inflammatory Disorders in Pregnancy (DP-iDP) by the Austrian Science Fund FWF (Doc 31-B26) and the Medical University of Graz, Austria.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>The authors thank Markus Absenger Novak from the Imaging core facility at the Center for Medical Research (ZMF) for advice on HCS set-up and analysis. The authors thank Renate Michlmaier for continuous technical support and Bettina Amtmann for patient acquisition.</p>
</ack>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2022.1095879/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2022.1095879/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet_1.pdf" id="SM1" mimetype="application/pdf"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<article-title>Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222</article-title>. <source>Obstet Gynecol</source> (<year>2020</year>) <volume>135</volume>:<page-range>e237&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/AOG.0000000000003891</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Practice Bulletin No</surname> <given-names>ACOG</given-names>
</name>
</person-group>. <article-title>203: Chronic hypertension in pregnancy</article-title>. <source>Obstet Gynecol</source> (<year>2019</year>) <volume>133</volume>:<page-range>e26&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/AOG.0000000000003020</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Magee</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Kenny</surname> <given-names>LC</given-names>
</name>
<name>
<surname>Karumanchi</surname> <given-names>SA</given-names>
</name>
<name>
<surname>McCarthy</surname> <given-names>FP</given-names>
</name>
<name>
<surname>Saito</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Hypertensive disorders of pregnancy</article-title>. <source>Hypertension</source> (<year>2018</year>) <volume>72</volume>:<fpage>24</fpage>&#x2013;<lpage>43</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.117.10803</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>W&#xf3;jtowicz</surname> <given-names>A</given-names>
</name>
<name>
<surname>Zembala-Szczerba</surname> <given-names>M</given-names>
</name>
<name>
<surname>Babczyk</surname> <given-names>D</given-names>
</name>
<name>
<surname>Ko&#x142;odziejczyk-Pietruszka</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lewaczy&#x144;ska</surname> <given-names>O</given-names>
</name>
<name>
<surname>Huras</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Early-and late-onset preeclampsia: A comprehensive cohort study of laboratory and clinical findings according to the new ISHHP criteria</article-title>. <source>Int J Hypertens</source> (<year>2019</year>) <volume>2019</volume>:<elocation-id>4108271</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2019/4108271</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>von Dadelszen</surname> <given-names>P</given-names>
</name>
<name>
<surname>Magee</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Roberts</surname> <given-names>JM</given-names>
</name>
</person-group>. <article-title>Subclassification of preeclampsia</article-title>. <source>Hypertens Pregnancy</source> (<year>2003</year>) <volume>22</volume>:<page-range>143&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1081/PRG-120021060</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tranquilli</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Zeeman</surname> <given-names>GG</given-names>
</name>
<name>
<surname>Dekker</surname> <given-names>G</given-names>
</name>
<name>
<surname>Sibai</surname> <given-names>BM</given-names>
</name>
</person-group>. <article-title>The definition of severe and early-onset preeclampsia. statements from the international society for the study of hypertension in pregnancy (ISSHP)</article-title>. <source>Pregnancy Hypertension: Int J Women&#x2019;s Cardiovasc Health</source> (<year>2013</year>) <volume>3</volume>:<page-range>44&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.PREGHY.2012.11.001</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huppertz</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Placental origins of preeclampsia: Challenging the current hypothesis</article-title>. <source>Hypertension</source> (<year>2008</year>) <volume>51</volume>:<page-range>970&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.107.107607</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>XL</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>PL</given-names>
</name>
<name>
<surname>Xue</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Gou</surname> <given-names>WL</given-names>
</name>
<name>
<surname>Tong</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Q</given-names>
</name>
</person-group>. <article-title>An analysis of the differences between early and late preeclampsia with severe hypertension</article-title>. <source>Pregnancy Hypertension: Int J Women&#x2019;s Cardiovasc Health</source> (<year>2016</year>) <volume>6</volume>:<fpage>47</fpage>&#x2013;<lpage>52</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.PREGHY.2015.12.003</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelson</surname> <given-names>DB</given-names>
</name>
<name>
<surname>Ziadie</surname> <given-names>MS</given-names>
</name>
<name>
<surname>McIntire</surname> <given-names>DD</given-names>
</name>
<name>
<surname>Rogers</surname> <given-names>BB</given-names>
</name>
<name>
<surname>Leveno</surname> <given-names>KJ</given-names>
</name>
</person-group>. <article-title>Placental pathology suggesting that preeclampsia is more than one disease</article-title>. <source>Am J Obstet Gynecol</source> (<year>2014</year>) <volume>210</volume>:<fpage>66</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.AJOG.2013.09.010</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stergiotou</surname> <given-names>I</given-names>
</name>
<name>
<surname>Crispi</surname> <given-names>F</given-names>
</name>
<name>
<surname>Valenzuela-Alcaraz</surname> <given-names>B</given-names>
</name>
<name>
<surname>Bijnens</surname> <given-names>B</given-names>
</name>
<name>
<surname>Gratacos</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>Patterns of maternal vascular remodeling and responsiveness in early- versus late-onset preeclampsia</article-title>. <source>Am J Obstet Gynecol</source> (<year>2013</year>) <volume>209</volume>:<fpage>558</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.AJOG.2013.07.030</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>del Gaudio</surname> <given-names>I</given-names>
</name>
<name>
<surname>Sasset</surname> <given-names>L</given-names>
</name>
<name>
<surname>di Lorenzo</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wadsack</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Sphingolipid signature of human feto-placental vasculature in preeclampsia</article-title>. <source>Int J Mol Sci</source> (<year>2020</year>) <volume>21</volume>(<issue>3</issue>):<elocation-id>1019</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms21031019</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murthi</surname> <given-names>P</given-names>
</name>
<name>
<surname>Pinar</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Dimitriadis</surname> <given-names>E</given-names>
</name>
<name>
<surname>Samuel</surname> <given-names>CS</given-names>
</name>
</person-group>. <article-title>Inflammasomes&#x2013;a molecular link for altered immunoregulation and inflammation mediated vascular dysfunction in preeclampsia</article-title>. <source>Int J Mol Sci</source> (<year>2020</year>) <volume>21</volume>:<elocation-id>1406</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/IJMS21041406</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borzychowski</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Sargent</surname> <given-names>IL</given-names>
</name>
<name>
<surname>Redman</surname> <given-names>CWG</given-names>
</name>
</person-group>. <article-title>Inflammation and pre-eclampsia</article-title>. <source>Semin Fetal Neonatal Med</source> (<year>2006</year>) <volume>11</volume>:<page-range>309&#x2013;16</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.SINY.2006.04.001</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname> <given-names>A</given-names>
</name>
<name>
<surname>Satyam</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sharma</surname> <given-names>JB</given-names>
</name>
</person-group>. <article-title>Leptin, IL-10 and inflammatory markers (TNF-&#x3b1;, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women</article-title>. <source>Am J Reprod Immunol</source> (<year>2007</year>) <volume>58</volume>:<fpage>21</fpage>&#x2013;<lpage>30</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/J.1600-0897.2007.00486.X</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vishnyakova</surname> <given-names>P</given-names>
</name>
<name>
<surname>Poltavets</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nikitina</surname> <given-names>M</given-names>
</name>
<name>
<surname>Muminova</surname> <given-names>K</given-names>
</name>
<name>
<surname>Potapova</surname> <given-names>A</given-names>
</name>
<name>
<surname>Vtorushina</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Preeclampsia: inflammatory signature of decidual cells in early manifestation of disease</article-title>. <source>Placenta</source> (<year>2021</year>) <volume>104</volume>:<page-range>277&#x2013;83</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.placenta.2021.01.011</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aneman</surname> <given-names>I</given-names>
</name>
<name>
<surname>Pienaar</surname> <given-names>D</given-names>
</name>
<name>
<surname>Suvakov</surname> <given-names>S</given-names>
</name>
<name>
<surname>Simic</surname> <given-names>TP</given-names>
</name>
<name>
<surname>Garovic</surname> <given-names>VD</given-names>
</name>
<name>
<surname>McClements</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Mechanisms of key innate immune cells in early- and late-onset preeclampsia</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>1864/XML/NLM</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/FIMMU.2020.01864/XML/NLM</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname> <given-names>X</given-names>
</name>
<name>
<surname>Ghaemi</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Ando</surname> <given-names>K</given-names>
</name>
<name>
<surname>Peterson</surname> <given-names>LS</given-names>
</name>
<name>
<surname>Ganio</surname> <given-names>EA</given-names>
</name>
<name>
<surname>Tsai</surname> <given-names>AS</given-names>
</name>
<etal/>
</person-group>. <article-title>Differential dynamics of the maternal immune system in healthy pregnancy and preeclampsia</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>1305/BIBTEX</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/FIMMU.2019.01305/BIBTEX</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broekhuizen</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hitzerd</surname> <given-names>E</given-names>
</name>
<name>
<surname>van den Bosch</surname> <given-names>TPP</given-names>
</name>
<name>
<surname>Dumas</surname> <given-names>J</given-names>
</name>
<name>
<surname>Verdijk</surname> <given-names>RM</given-names>
</name>
<name>
<surname>van Rijn</surname> <given-names>BB</given-names>
</name>
<etal/>
</person-group>. <article-title>The placental innate immune system is altered in early-onset preeclampsia, but not in late-onset preeclampsia</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>780043/BIBTEX</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/FIMMU.2021.780043/BIBTEX</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ruan</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>PJ</given-names>
</name>
</person-group>. <article-title>Immune imbalance is associated with the development of preeclampsia</article-title>. <source>Med (United States)</source> (<year>2019</year>) <volume>98</volume>(<issue>14</issue>):<elocation-id>e15080</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/MD.0000000000015080</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atri</surname> <given-names>C</given-names>
</name>
<name>
<surname>Guerfali</surname> <given-names>FZ</given-names>
</name>
<name>
<surname>Laouini</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Role of human macrophage polarization in inflammation during infectious diseases</article-title>. <source>Int J Mol Sci</source> (<year>2018</year>) <volume>19</volume>(<issue>6</issue>):<elocation-id>1801</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/IJMS19061801</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapouri-Moghaddam</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mohammadian</surname> <given-names>S</given-names>
</name>
<name>
<surname>Vazini</surname> <given-names>H</given-names>
</name>
<name>
<surname>Taghadosi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Esmaeili</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Mardani</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophage plasticity, polarization, and function in health and disease</article-title>. <source>J Cell Physiol</source> (<year>2018</year>) <volume>233</volume>:<page-range>6425&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jcp.26429</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname> <given-names>J</given-names>
</name>
<name>
<surname>Schmidt</surname> <given-names>SV</given-names>
</name>
<name>
<surname>Sander</surname> <given-names>J</given-names>
</name>
<name>
<surname>Draffehn</surname> <given-names>A</given-names>
</name>
<name>
<surname>Krebs</surname> <given-names>W</given-names>
</name>
<name>
<surname>Quester</surname> <given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Transcriptome-based network analysis reveals a spectrum model of human macrophage activation</article-title>. <source>Immunity</source> (<year>2014</year>) <volume>40</volume>:<fpage>274</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.IMMUNI.2014.01.006</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takiguchi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>CX</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>CWT</given-names>
</name>
<name>
<surname>Sahin</surname> <given-names>B</given-names>
</name>
<name>
<surname>Whalen</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Milne</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophages with reduced expressions of classical M1 and M2 surface markers in human bronchoalveolar lavage fluid exhibit pro-inflammatory gene signatures</article-title>. <source>Sci Rep</source> (<year>2021</year>) <volume>11</volume>:<fpage>1</fpage>&#x2013;<lpage>11</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-021-87720-y</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porcheray</surname> <given-names>F</given-names>
</name>
<name>
<surname>Viaud</surname> <given-names>S</given-names>
</name>
<name>
<surname>Rimaniol</surname> <given-names>A-C</given-names>
</name>
<name>
<surname>L&#xe9;one</surname> <given-names>C</given-names>
</name>
<name>
<surname>Samah</surname> <given-names>B</given-names>
</name>
<name>
<surname>Dereuddre-Bosquet</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophage activation switching: an asset for the resolution of inflammation</article-title>. <source>Clin Exp Immunol</source> (<year>2005</year>) <volume>142</volume>:<fpage>481</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/J.1365-2249.2005.02934.X</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oshi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tokumaru</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Asaoka</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>L</given-names>
</name>
<name>
<surname>Satyananda</surname> <given-names>V</given-names>
</name>
<name>
<surname>Matsuyama</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>M1 macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer</article-title>. <source>Sci Rep</source> (<year>2020</year>) <volume>10</volume>:<fpage>1</fpage>&#x2013;<lpage>12</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-020-73624-w</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loegl</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hiden</surname> <given-names>U</given-names>
</name>
<name>
<surname>Nussbaumer</surname> <given-names>E</given-names>
</name>
<name>
<surname>Schliefsteiner</surname> <given-names>C</given-names>
</name>
<name>
<surname>Cvitic</surname> <given-names>S</given-names>
</name>
<name>
<surname>Lang</surname> <given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Hofbauer cells of M2a, M2b and M2c polarization may regulate feto-placental angiogenesis</article-title>. <source>Reproduction</source> (<year>2016</year>) <volume>152</volume>:<page-range>447&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1530/REP-16-0159</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez</surname> <given-names>FO</given-names>
</name>
<name>
<surname>Gordon</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>The M1 and M2 paradigm of macrophage activation: time for reassessment</article-title>. <source>F1000Prime Rep</source> (<year>2014</year>) <volume>6</volume>:<elocation-id>13</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.12703/P6-13</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turco</surname> <given-names>MY</given-names>
</name>
<name>
<surname>Moffett</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Development of the human placenta</article-title>. <source>Development</source> (<year>2019</year>) <volume>146</volume>(<issue>22</issue>):<elocation-id>dev163428</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1242/DEV.163428</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reyes</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wolfe</surname> <given-names>B</given-names>
</name>
<name>
<surname>Golos</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>&#x201c;Hofbauer cells: Placental macrophages of fetal origin&#x201d;</article-title>. In: <source>Results Problems Cell Differentiation</source> (<year>2017</year>) <volume>62</volume>:<fpage>45</fpage>&#x2013;<lpage>60</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978-3-319-54090-0_3</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schliefsteiner</surname> <given-names>C</given-names>
</name>
<name>
<surname>Ibesich</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wadsack</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Placental hofbauer cell polarization resists inflammatory cues <italic>In vitro</italic>
</article-title>. <source>Int J Mol Sci</source> (<year>2020</year>) <volume>21</volume>(<issue>3</issue>):<elocation-id>736</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms21030736</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schliefsteiner</surname> <given-names>C</given-names>
</name>
<name>
<surname>Peinhaupt</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kopp</surname> <given-names>S</given-names>
</name>
<name>
<surname>L&#xf6;gl</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lang-Olip</surname> <given-names>I</given-names>
</name>
<name>
<surname>Hiden</surname> <given-names>U</given-names>
</name>
<etal/>
</person-group>. <article-title>Human placental hofbauer cells maintain an anti-inflammatory M2 phenotype despite the presence of gestational diabetes mellitus</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<elocation-id>888</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2017.00888</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Niven-Fairchild</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tadesse</surname> <given-names>S</given-names>
</name>
<name>
<surname>Norwitz</surname> <given-names>ER</given-names>
</name>
<name>
<surname>Buhimschi</surname> <given-names>CS</given-names>
</name>
<name>
<surname>Buhimschi</surname> <given-names>IA</given-names>
</name>
<etal/>
</person-group>. <article-title>Glucocorticoids enhance CD163 expression in placental hofbauer cells</article-title>. <source>Endocrinology</source> (<year>2013</year>) <volume>154</volume>:<page-range>471&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1210/EN.2012-1575</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>SY</given-names>
</name>
<name>
<surname>Romero</surname> <given-names>R</given-names>
</name>
<name>
<surname>Tarca</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Bhatti</surname> <given-names>G</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Methylome of fetal and maternal monocytes and macrophages at the feto-maternal interface</article-title>. <source>Am J Reprod Immunol</source> (<year>2012</year>) <volume>68</volume>:<fpage>8</fpage>&#x2013;<lpage>27</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/J.1600-0897.2012.01108.X</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Goldstein</surname> <given-names>J</given-names>
</name>
<name>
<surname>Braverman</surname> <given-names>M</given-names>
</name>
<name>
<surname>Salafia</surname> <given-names>C</given-names>
</name>
<name>
<surname>Buckley</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>The phenotype of human placental macrophages and its variation with gestational age</article-title>(<year>1988</year>) (Accessed <access-date>November 5, 2021</access-date>).</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zulu</surname> <given-names>MZ</given-names>
</name>
<name>
<surname>Martinez</surname> <given-names>FO</given-names>
</name>
<name>
<surname>Gordon</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gray</surname> <given-names>CM</given-names>
</name>
</person-group>. <article-title>The elusive role of placental macrophages: The hofbauer cell</article-title>. <source>J Innate Immun</source> (<year>2019</year>) <volume>11</volume>:<page-range>447&#x2013;56</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1159/000497416</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Appios</surname> <given-names>A</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Dutkiewicz</surname> <given-names>R</given-names>
</name>
<name>
<surname>Donde</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>CYC</given-names>
</name>
<etal/>
</person-group>. <article-title>Phenotypic and functional characterization of first-trimester human placental macrophages, hofbauer cells</article-title>. <source>J Exp Med</source> (<year>2020</year>) <volume>218</volume>(<issue>1</issue>):<fpage>e20200891</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/JEM.20200891</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname> <given-names>OM</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Niven-Fairchild</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tadesse</surname> <given-names>S</given-names>
</name>
<name>
<surname>Krikun</surname> <given-names>G</given-names>
</name>
<name>
<surname>Norwitz</surname> <given-names>ER</given-names>
</name>
<etal/>
</person-group>. <article-title>Toll-like receptor-mediated responses by placental hofbauer cells (HBCs): A potential pro-inflammatory role for fetal M2 macrophages</article-title>. <source>Am J Reprod Immunol</source> (<year>2015</year>) <volume>73</volume>:<fpage>22</fpage>&#x2013;<lpage>35</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/aji.12336</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Svensson-Arvelund</surname> <given-names>J</given-names>
</name>
<name>
<surname>Mehta</surname> <given-names>RB</given-names>
</name>
<name>
<surname>Lindau</surname> <given-names>R</given-names>
</name>
<name>
<surname>Mirrasekhian</surname> <given-names>E</given-names>
</name>
<name>
<surname>Rodriguez-Martinez</surname> <given-names>H</given-names>
</name>
<name>
<surname>Berg</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>The human fetal placenta promotes tolerance against the semiallogeneic fetus by inducing regulatory T cells and homeostatic M2 macrophages</article-title>. <source>J Immunol</source> (<year>2015</year>) <volume>194</volume>:<page-range>1534&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/JIMMUNOL.1401536</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cervar</surname> <given-names>M</given-names>
</name>
<name>
<surname>Blaschitz</surname> <given-names>A</given-names>
</name>
<name>
<surname>Dohr</surname> <given-names>G</given-names>
</name>
<name>
<surname>Desoye</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Paracrine regulation of distinct trophoblast functions <italic>in vitro</italic> by placental macrophages</article-title>. <source>Cell Tissue Res</source> (<year>1999</year>) <volume>295</volume>:<fpage>297</fpage>&#x2013;<lpage>305</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/S004410051236</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Katabuchi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Araki</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nishimura</surname> <given-names>R</given-names>
</name>
<name>
<surname>Okamura</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Human villous macrophage-conditioned media enhance human trophoblast growth and differentiation</article-title>. <source>In Vitro Biol Reprod</source> (<year>2000</year>) <volume>62</volume>:<page-range>1075&#x2013;83</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1095/BIOLREPROD62.4.1075</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anteby</surname> <given-names>EY</given-names>
</name>
<name>
<surname>Natanson-Yaron</surname> <given-names>S</given-names>
</name>
<name>
<surname>Greenfield</surname> <given-names>C</given-names>
</name>
<name>
<surname>Goldman-Wohl</surname> <given-names>D</given-names>
</name>
<name>
<surname>Haimov-Kochman</surname> <given-names>R</given-names>
</name>
<name>
<surname>Holzer</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Human placental hofbauer cells express sprouty proteins: a possible modulating mechanism of villous branching</article-title>. <source>Placenta</source> (<year>2005</year>) <volume>26</volume>:<page-range>476&#x2013;83</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.PLACENTA.2004.08.008</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seval</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Korgun</surname> <given-names>ET</given-names>
</name>
<name>
<surname>Demir</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Hofbauer cells in early human placenta: possible implications in vasculogenesis and angiogenesis</article-title>. <source>Placenta</source> (<year>2007</year>) <volume>28</volume>:<page-range>841&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.PLACENTA.2007.01.010</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>ben Amara</surname> <given-names>A</given-names>
</name>
<name>
<surname>Gorvel</surname> <given-names>L</given-names>
</name>
<name>
<surname>Baulan</surname> <given-names>K</given-names>
</name>
<name>
<surname>Derain-Court</surname> <given-names>J</given-names>
</name>
<name>
<surname>Buffat</surname> <given-names>C</given-names>
</name>
<name>
<surname>V&#xe9;rollet</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Placental macrophages are impaired in chorioamnionitis, an infectious pathology of the placenta</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>191</volume>:<page-range>5501&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1300988</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vinnars</surname> <given-names>M-TN</given-names>
</name>
<name>
<surname>Rindsj&#xf6;</surname> <given-names>E</given-names>
</name>
<name>
<surname>Ghazi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sundberg</surname> <given-names>A</given-names>
</name>
<name>
<surname>Papadogiannakis</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>The number of CD68+ (Hofbauer) cells is decreased in placentas with chorioamnionitis and with advancing gestational age</article-title>. <source>Pediatr Dev Pathol</source> (<year>2010</year>) <volume>13</volume>:<page-range>300&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2350/09-03-0632-OA.1</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toti</surname> <given-names>P</given-names>
</name>
<name>
<surname>Arcuri</surname> <given-names>F</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Schatz</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zambrano</surname> <given-names>E</given-names>
</name>
<name>
<surname>Mor</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Focal increases of fetal macrophages in placentas from pregnancies with histological chorioamnionitis: Potential role of fibroblast monocyte chemotactic protein-1</article-title>. <source>Am J Reprod Immunol</source> (<year>2011</year>) <volume>65</volume>:<page-range>470&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1600-0897.2010.00927.x</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Romero</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>YM</given-names>
</name>
<name>
<surname>Friel</surname> <given-names>L</given-names>
</name>
<name>
<surname>Espinoza</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Involvement of hofbauer cells and maternal T cells in villitis of unknown aetiology</article-title>. <source>Histopathology</source> (<year>2008</year>) <volume>52</volume>:<page-range>457&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1365-2559.2008.02964.x</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quicke</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Bowen</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>EL</given-names>
</name>
<name>
<surname>McDonald</surname> <given-names>CE</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>H</given-names>
</name>
<name>
<surname>O&#x2019;Neal</surname> <given-names>JT</given-names>
</name>
<etal/>
</person-group>. <article-title>Zika virus infects human placental macrophages</article-title>. <source>Cell Host Microbe</source> (<year>2016</year>) <volume>20</volume>:<fpage>83</fpage>&#x2013;<lpage>90</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.CHOM.2016.05.015</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Tadesse</surname> <given-names>S</given-names>
</name>
<name>
<surname>Norwitz</surname> <given-names>E</given-names>
</name>
<name>
<surname>Mor</surname> <given-names>G</given-names>
</name>
<name>
<surname>Abrahams</surname> <given-names>VM</given-names>
</name>
<name>
<surname>Guller</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Isolation of hofbauer cells from human term placentas with high yield and purity</article-title>. <source>Am J Reprod Immunol</source> (<year>2011</year>) <volume>66</volume>:<page-range>336&#x2013;48</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1600-0897.2011.01006.x</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bankhead</surname> <given-names>P</given-names>
</name>
<name>
<surname>Loughrey</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Fern&#xe1;ndez</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Dombrowski</surname> <given-names>Y</given-names>
</name>
<name>
<surname>McArt</surname> <given-names>DG</given-names>
</name>
<name>
<surname>Dunne</surname> <given-names>PD</given-names>
</name>
<etal/>
</person-group>. <article-title>QuPath: Open source software for digital pathology image analysis</article-title>. <source>Sci Rep</source> (<year>2017</year>) <volume>7</volume>:<fpage>1</fpage>&#x2013;<lpage>7</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-017-17204-5</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moldenhauer</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Stanek</surname> <given-names>J</given-names>
</name>
<name>
<surname>Warshak</surname> <given-names>C</given-names>
</name>
<name>
<surname>Khoury</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sibai</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>The frequency and severity of placental findings in women with preeclampsia are gestational age dependent</article-title>. <source>Am J Obstet Gynecol</source> (<year>2003</year>) <volume>189</volume>:<page-range>1173&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1067/S0002-9378(03)00576-3</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Buhimschi</surname> <given-names>IA</given-names>
</name>
<name>
<surname>Buhimschi</surname> <given-names>CS</given-names>
</name>
<name>
<surname>Tadesse</surname> <given-names>S</given-names>
</name>
<name>
<surname>Norwitz</surname> <given-names>E</given-names>
</name>
<name>
<surname>Niven-Fairchild</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Decreased levels of folate receptor-&#x3b2; and reduced numbers of fetal macrophages (Hofbauer cells) in placentas from pregnancies with severe pre-eclampsia</article-title>. <source>Am J Reprod Immunol</source> (<year>2013</year>) <volume>70</volume>:<page-range>104&#x2013;15</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/AJI.12112</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McWhorter</surname> <given-names>FY</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Nguyen</surname> <given-names>P</given-names>
</name>
<name>
<surname>Chung</surname> <given-names>T</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>WF</given-names>
</name>
</person-group>. <article-title>Modulation of macrophage phenotype by cell shape</article-title>. <source>Proc Natl Acad Sci</source> (<year>2013</year>) <volume>110</volume>:<page-range>17253&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/PNAS.1308887110</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porta</surname> <given-names>C</given-names>
</name>
<name>
<surname>Riboldi</surname> <given-names>E</given-names>
</name>
<name>
<surname>Ippolito</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sica</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Molecular and epigenetic basis of macrophage polarized activation</article-title>. <source>Semin Immunol</source> (<year>2015</year>) <volume>27</volume>:<page-range>237&#x2013;48</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.SMIM.2015.10.003</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Lx</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Hj</given-names>
</name>
<name>
<surname>Rong</surname> <given-names>X</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>M2b macrophage polarization and its roles in diseases</article-title>. <source>J Leukoc Biol</source> (<year>2019</year>) <volume>106</volume>:<page-range>345&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/JLB.3RU1018-378RR</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez</surname> <given-names>FO</given-names>
</name>
<name>
<surname>Sica</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mantovani</surname> <given-names>A</given-names>
</name>
<name>
<surname>Locati</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Macrophage activation and polarization</article-title>. <source>Front Bioscience</source> (<year>2008</year>) <volume>13</volume>:<page-range>453&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2741/2692/PDF</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Negishi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ohba</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yanai</surname> <given-names>H</given-names>
</name>
<name>
<surname>Takaoka</surname> <given-names>A</given-names>
</name>
<name>
<surname>Honma</surname> <given-names>K</given-names>
</name>
<name>
<surname>Yui</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Negative regulation of toll-like-receptor signaling by IRF-4</article-title>. <source>Proc Natl Acad Sci</source> (<year>2005</year>) <volume>102</volume>:<page-range>15989&#x2013;94</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/PNAS.0508327102</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takaoka</surname> <given-names>A</given-names>
</name>
<name>
<surname>Yanai</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kondo</surname> <given-names>S</given-names>
</name>
<name>
<surname>Duncan</surname> <given-names>G</given-names>
</name>
<name>
<surname>Negishi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Mizutani</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Integral role of IRF-5 in the gene induction programme activated by toll-like receptors</article-title>. <source>Nature</source> (<year>2005</year>) <volume>434</volume>:<page-range>243&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature03308</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krausgruber</surname> <given-names>T</given-names>
</name>
<name>
<surname>Blazek</surname> <given-names>K</given-names>
</name>
<name>
<surname>Smallie</surname> <given-names>T</given-names>
</name>
<name>
<surname>Alzabin</surname> <given-names>S</given-names>
</name>
<name>
<surname>Lockstone</surname> <given-names>H</given-names>
</name>
<name>
<surname>Sahgal</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses</article-title>. <source>Nat Immunol</source> (<year>2011</year>) <volume>12</volume>:<page-range>231&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ni.1990</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Honma</surname> <given-names>K</given-names>
</name>
<name>
<surname>Udono</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kohno</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yamamoto</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ogawa</surname> <given-names>A</given-names>
</name>
<name>
<surname>Takemori</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Interferon regulatory factor 4 negatively regulates the production of proinflammatory cytokines by macrophages in response to LPS</article-title>. <source>Proc Natl Acad Sci</source> (<year>2005</year>) <volume>102</volume>:<page-range>16001&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/PNAS.0504226102</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raggi</surname> <given-names>F</given-names>
</name>
<name>
<surname>Pelassa</surname> <given-names>S</given-names>
</name>
<name>
<surname>Pierobon</surname> <given-names>D</given-names>
</name>
<name>
<surname>Penco</surname> <given-names>F</given-names>
</name>
<name>
<surname>Gattorno</surname> <given-names>M</given-names>
</name>
<name>
<surname>Novelli</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Regulation of human macrophage M1&#x2013;M2 polarization balance by hypoxia and the triggering receptor expressed on myeloid cells-1</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>0</volume>:<elocation-id>1097</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/FIMMU.2017.01097</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makita</surname> <given-names>N</given-names>
</name>
<name>
<surname>Hizukuri</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yamashiro</surname> <given-names>K</given-names>
</name>
<name>
<surname>Murakawa</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hayashi</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>IL-10 enhances the phenotype of M2 macrophages induced by IL-4 and confers the ability to increase eosinophil migration</article-title>. <source>Int Immunol</source> (<year>2015</year>) <volume>27</volume>:<page-range>131&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/INTIMM/DXU090</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernando</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Reyes</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Iannuzzi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Leung</surname> <given-names>G</given-names>
</name>
<name>
<surname>McKay</surname> <given-names>DM</given-names>
</name>
</person-group>. <article-title>The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages</article-title>. <source>PloS One</source> (<year>2014</year>) <volume>9</volume>:<elocation-id>e94188</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/JOURNAL.PONE.0094188</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frank</surname> <given-names>PG</given-names>
</name>
<name>
<surname>Lisanti</surname> <given-names>MP</given-names>
</name>
</person-group>. <article-title>ICAM-1: role in inflammation and in the regulation of vascular permeability</article-title>. <source>Am J Physiol Heart Circ Physiol</source> (<year>2008</year>) <volume>295</volume>:<fpage>H926</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/AJPHEART.00779.2008</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>G</given-names>
</name>
<name>
<surname>Su</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>BH</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>T</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>DR</given-names>
</name>
<etal/>
</person-group>. <article-title>High-throughput phenotypic screen and transcriptional analysis identify new compounds and targets for macrophage reprogramming</article-title>. <source>Nat Commun</source> (<year>2021</year>) <volume>12</volume>:<fpage>1</fpage>&#x2013;<lpage>14</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-021-21066-x</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Joo</surname> <given-names>D</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>S-C</given-names>
</name>
</person-group>. <article-title>NF-&#x3ba;B signaling in inflammation</article-title>. <source>Signal Transduction Targeted Ther</source> (<year>2017</year>) <volume>2</volume>:<fpage>1</fpage>&#x2013;<lpage>9</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/sigtrans.2017.23</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murray</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Allen</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Biswas</surname> <given-names>SK</given-names>
</name>
<name>
<surname>Fisher</surname> <given-names>EA</given-names>
</name>
<name>
<surname>Gilroy</surname> <given-names>DW</given-names>
</name>
<name>
<surname>Goerdt</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophage activation and polarization: Nomenclature and experimental guidelines</article-title>. <source>Immunity</source> (<year>2014</year>) <volume>41</volume>:<fpage>14</fpage>&#x2013;<lpage>20</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.IMMUNI.2014.06.008</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palanisamy</surname> <given-names>V</given-names>
</name>
<name>
<surname>Jakymiw</surname> <given-names>A</given-names>
</name>
<name>
<surname>van Tubergen</surname> <given-names>EA</given-names>
</name>
<name>
<surname>D&#x2019;Silva</surname> <given-names>NJ</given-names>
</name>
<name>
<surname>Kirkwood</surname> <given-names>KL</given-names>
</name>
</person-group>. <article-title>Control of cytokine mRNA expression by RNA-binding proteins and microRNAs</article-title>. <source>J Dent Res</source> (<year>2012</year>) <volume>91</volume>:<fpage>651</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/0022034512437372</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rath</surname> <given-names>M</given-names>
</name>
<name>
<surname>M&#xfc;ller</surname> <given-names>I</given-names>
</name>
<name>
<surname>Kropf</surname> <given-names>P</given-names>
</name>
<name>
<surname>Closs</surname> <given-names>EI</given-names>
</name>
<name>
<surname>Munder</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Metabolism <italic>via</italic> arginase or nitric oxide synthase: Two competing arginine pathways in macrophages</article-title>. <source>Front Immunol</source> (<year>2014</year>) <volume>0</volume>:<elocation-id>532</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/FIMMU.2014.00532</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Choksi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>K</given-names>
</name>
<name>
<surname>Pobezinskaya</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Linnoila</surname> <given-names>I</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Z-G</given-names>
</name>
</person-group>. <article-title>ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages</article-title>. <source>Cell Res</source> (<year>2013</year>) <volume>23</volume>:<fpage>898</fpage>&#x2013;<lpage>914</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cr.2013.75</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rendra</surname> <given-names>E</given-names>
</name>
<name>
<surname>Riabov</surname> <given-names>V</given-names>
</name>
<name>
<surname>Mossel</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Sevastyanova</surname> <given-names>T</given-names>
</name>
<name>
<surname>Harmsen</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Kzhyshkowska</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Reactive oxygen species (ROS) in macrophage activation and function in diabetes</article-title>. <source>Immunobiology</source> (<year>2019</year>) <volume>224</volume>:<page-range>242&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.IMBIO.2018.11.010</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griess</surname> <given-names>B</given-names>
</name>
<name>
<surname>Mir</surname> <given-names>S</given-names>
</name>
<name>
<surname>Datta</surname> <given-names>K</given-names>
</name>
<name>
<surname>Teoh-Fitzgerald</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Scavenging reactive oxygen species selectively inhibits M2 macrophage polarization and their pro-tumorigenic function in part, <italic>via</italic> Stat3 suppression</article-title>. <source>Free Radic Biol Med</source> (<year>2020</year>) <volume>147</volume>:<fpage>48</fpage>&#x2013;<lpage>60</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.FREERADBIOMED.2019.12.018</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kl&#xf6;ditz</surname> <given-names>K</given-names>
</name>
<name>
<surname>Fadeel</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Three cell deaths and a funeral: macrophage clearance of cells undergoing distinct modes of cell death</article-title>. <source>Cell Death Discov</source> (<year>2019</year>) <volume>5</volume>:<fpage>1</fpage>&#x2013;<lpage>9</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41420-019-0146-x</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reyes</surname> <given-names>L</given-names>
</name>
<name>
<surname>Golos</surname> <given-names>TG</given-names>
</name>
</person-group>. <article-title>Hofbauer cells: Their role in healthy and complicated pregnancy</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>2628</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2018.02628</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raguema</surname> <given-names>N</given-names>
</name>
<name>
<surname>Moustadraf</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bertagnolli</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Immune and apoptosis mechanisms regulating placental development and vascularization in preeclampsia</article-title>. <source>Front Physiol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>98</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphys.2020.00098</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phipps</surname> <given-names>EA</given-names>
</name>
<name>
<surname>Thadhani</surname> <given-names>R</given-names>
</name>
<name>
<surname>Benzing</surname> <given-names>T</given-names>
</name>
<name>
<surname>Karumanchi</surname> <given-names>SA</given-names>
</name>
</person-group>. <article-title>Pre-eclampsia: pathogenesis, novel diagnostics and therapies</article-title>. <source>Nat Rev Nephrol</source> (<year>2019</year>) <volume>15</volume>:<page-range>275&#x2013;89</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41581-019-0119-6</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brew</surname> <given-names>K</given-names>
</name>
<name>
<surname>Nagase</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity</article-title>. <source>Biochim Biophys Acta</source> (<year>2010</year>) <volume>1803</volume>:<fpage>55</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.BBAMCR.2010.01.003</pub-id>
</citation>
</ref>
<ref id="B77">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cataldo</surname> <given-names>DD</given-names>
</name>
<name>
<surname>Gueders</surname> <given-names>M</given-names>
</name>
<name>
<surname>Munaut</surname> <given-names>C</given-names>
</name>
<name>
<surname>Rocks</surname> <given-names>N</given-names>
</name>
<name>
<surname>Bartsch</surname> <given-names>P</given-names>
</name>
<name>
<surname>Foidart</surname> <given-names>J-M</given-names>
</name>
<etal/>
</person-group>. <article-title>Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases mRNA transcripts in the bronchial secretions of asthmatics</article-title>. <source>Lab Invest</source> (<year>2004</year>) <volume>84</volume>:<page-range>418&#x2013;24</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/labinvest.3700063</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Visse</surname> <given-names>R</given-names>
</name>
<name>
<surname>Nagase</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Matrix metalloproteinases and tissue inhibitors of metalloproteinases</article-title>. <source>Circ Res</source> (<year>2003</year>) <volume>92</volume>:<page-range>827&#x2013;39</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/01.RES.0000070112.80711.3D</pub-id>
</citation>
</ref>
<ref id="B79">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gardner</surname> <given-names>K</given-names>
</name>
<name>
<surname>Arnoczky</surname> <given-names>SP</given-names>
</name>
<name>
<surname>Caballero</surname> <given-names>O</given-names>
</name>
<name>
<surname>Lavagnino</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>The effect of stress-deprivation and cyclic loading on the TIMP/MMP ratio in tendon cells: An in vitro experimental study</article-title>. <source>Disabil Rehabil</source> (<year>2008</year>). <volume>30</volume>(<issue>20&#x2013;22</issue>):<page-range>1523&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/09638280701785395</pub-id>
</citation>
</ref>
<ref id="B80">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arpino</surname> <given-names>V</given-names>
</name>
<name>
<surname>Brock</surname> <given-names>M</given-names>
</name>
<name>
<surname>Gill</surname> <given-names>SE</given-names>
</name>
</person-group>. <article-title>The role of TIMPs in regulation of extracellular matrix proteolysis</article-title>. <source>Matrix Biol</source> (<year>2015</year>) <volume>44&#x2013;46</volume>:<page-range>247&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.MATBIO.2015.03.005</pub-id>
</citation>
</ref>
<ref id="B81">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Svensson</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jenmalm</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Matussek</surname> <given-names>A</given-names>
</name>
<name>
<surname>Geffers</surname> <given-names>R</given-names>
</name>
<name>
<surname>Berg</surname> <given-names>G</given-names>
</name>
<name>
<surname>Ernerudh</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Macrophages at the fetal&#x2013;maternal interface express markers of alternative activation and are induced by m-CSF and IL-10</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>187</volume>:<page-range>3671&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/JIMMUNOL.1100130</pub-id>
</citation>
</ref>
<ref id="B82">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rana</surname> <given-names>S</given-names>
</name>
<name>
<surname>Lemoine</surname> <given-names>E</given-names>
</name>
<name>
<surname>Granger</surname> <given-names>J</given-names>
</name>
<name>
<surname>Karumanchi</surname> <given-names>SA</given-names>
</name>
</person-group>. <article-title>Preeclampsia: Pathophysiology, challenges, and perspectives</article-title>. <source>Circ Res</source> (<year>2019</year>) <volume>124</volume>:<page-range>1094&#x2013;112</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.313276/FORMAT/EPUB</pub-id>
</citation>
</ref>
<ref id="B83">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>G</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Distinct placental molecular processes associated with early-onset and late-onset preeclampsia</article-title>. <source>Theranostics</source> (<year>2021</year>) <volume>11</volume>:<page-range>5028&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.7150/THNO.56141</pub-id>
</citation>
</ref>
<ref id="B84">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kovo</surname> <given-names>M</given-names>
</name>
<name>
<surname>Schreiber</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ben-Haroush</surname> <given-names>A</given-names>
</name>
<name>
<surname>Gold</surname> <given-names>E</given-names>
</name>
<name>
<surname>Golan</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bar</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>The placental component in early-onset and late-onset preeclampsia in relation to fetal growth restriction</article-title>. <source>Prenat Diagn</source> (<year>2012</year>) <volume>32</volume>:<page-range>632&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/PD.3872</pub-id>
</citation>
</ref>
<ref id="B85">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sohlberg</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mulic-Lutvica</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lindgren</surname> <given-names>P</given-names>
</name>
<name>
<surname>Ortiz-Nieto</surname> <given-names>F</given-names>
</name>
<name>
<surname>Wikstr&#xf6;m</surname> <given-names>AK</given-names>
</name>
<name>
<surname>Wikstr&#xf6;m</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Placental perfusion in normal pregnancy and early and late preeclampsia: A magnetic resonance imaging study</article-title>. <source>Placenta</source> (<year>2014</year>) <volume>35</volume>:<page-range>202&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.PLACENTA.2014.01.008</pub-id>
</citation>
</ref>
<ref id="B86">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mar&#xed;n</surname> <given-names>R</given-names>
</name>
<name>
<surname>Chiarello</surname> <given-names>DI</given-names>
</name>
<name>
<surname>Abad</surname> <given-names>C</given-names>
</name>
<name>
<surname>Rojas</surname> <given-names>D</given-names>
</name>
<name>
<surname>Toledo</surname> <given-names>F</given-names>
</name>
<name>
<surname>Sobrevia</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Oxidative stress and mitochondrial dysfunction in early-onset and late-onset preeclampsia</article-title>. <source>Biochim Biophys Acta (BBA) - Mol Basis Dis</source> (<year>2020</year>) <volume>1866</volume>:<elocation-id>165961</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.BBADIS.2020.165961</pub-id>
</citation>
</ref>
<ref id="B87">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saito</surname> <given-names>S</given-names>
</name>
<name>
<surname>Shiozaki</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nakashima</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sakai</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sasaki</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>The role of the immune system in preeclampsia</article-title>. <source>Mol Aspects Med</source> (<year>2007</year>) <volume>28</volume>:<fpage>192</fpage>&#x2013;<lpage>209</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.MAM.2007.02.006</pub-id>
</citation>
</ref>
<ref id="B88">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>DiFederico</surname> <given-names>E</given-names>
</name>
<name>
<surname>Genbacev</surname> <given-names>O</given-names>
</name>
<name>
<surname>Fisher</surname> <given-names>SJ</given-names>
</name>
</person-group>. <article-title>Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall</article-title>. <source>Am J Pathol</source> (<year>1999</year>) <volume>155</volume>:<fpage>293</fpage>&#x2013;<lpage>301</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0002-9440(10)65123-1</pub-id>
</citation>
</ref>
<ref id="B89">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>G</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xi</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Abnormal apoptosis of trophoblastic cells is related to the up-regulation of CYP11A gene in placenta of preeclampsia patients</article-title>. <source>PloS One</source> (<year>2013</year>) <volume>8</volume>:<elocation-id>e59609</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/JOURNAL.PONE.0059609</pub-id>
</citation>
</ref>
<ref id="B90">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mor</surname> <given-names>G</given-names>
</name>
<name>
<surname>Abrahams</surname> <given-names>VM</given-names>
</name>
</person-group>. <article-title>Potential role of macrophages as immunoregulators of pregnancy</article-title>. <source>Reprod Biol Endocrinol</source> (<year>2003</year>) <volume>1</volume>:<fpage>1</fpage>&#x2013;<lpage>8</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1477-7827-1-119/FIGURES/4</pub-id>
</citation>
</ref>
<ref id="B91">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joerink</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rindsj&#xf6;</surname> <given-names>E</given-names>
</name>
<name>
<surname>van Riel</surname> <given-names>B</given-names>
</name>
<name>
<surname>Alm</surname> <given-names>J</given-names>
</name>
<name>
<surname>Papadogiannakis</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Placental macrophage (Hofbauer cell) polarization is independent of maternal allergen-sensitization and presence of chorioamnionitis</article-title>. <source>Placenta</source> (<year>2011</year>) <volume>32</volume>:<page-range>380&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.PLACENTA.2011.02.003</pub-id>
</citation>
</ref>
<ref id="B92">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Satoh</surname> <given-names>T</given-names>
</name>
<name>
<surname>Takeuchi</surname> <given-names>O</given-names>
</name>
<name>
<surname>Vandenbon</surname> <given-names>A</given-names>
</name>
<name>
<surname>Yasuda</surname> <given-names>K</given-names>
</name>
<name>
<surname>Tanaka</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kumagai</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection</article-title>. <source>Nat Immunol</source> (<year>2010</year>) <volume>11</volume>:<page-range>936&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ni.1920</pub-id>
</citation>
</ref>
<ref id="B93">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeon</surname> <given-names>MK</given-names>
</name>
<name>
<surname>Romero</surname> <given-names>R</given-names>
</name>
<name>
<surname>Seo</surname> <given-names>YO</given-names>
</name>
<name>
<surname>Chong</surname> <given-names>JK</given-names>
</name>
<name>
<surname>Kilburn</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Armant</surname> <given-names>DR</given-names>
</name>
<etal/>
</person-group>. <article-title>Toll-like receptor 4: A potential link between &#x201c;danger signals,&#x201d; the innate immune system, and preeclampsia</article-title>? <source>Am J Obstet Gynecol</source> (<year>2005</year>) <volume>193</volume>:<page-range>921.e1&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.AJOG.2005.07.076</pub-id>
</citation>
</ref>
<ref id="B94">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>al Mamun</surname> <given-names>A</given-names>
</name>
<name>
<surname>Chauhan</surname> <given-names>A</given-names>
</name>
<name>
<surname>Qi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ngwa</surname> <given-names>C</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sharmeen</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Microglial IRF5-IRF4 regulatory axis regulates neuroinflammation after cerebral ischemia and impacts stroke outcomes</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2020</year>) <volume>117</volume>:<page-range>1742&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/PNAS.1914742117/-/DCSUPPLEMENTAL</pub-id>
</citation>
</ref>
<ref id="B95">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>el Chartouni</surname> <given-names>C</given-names>
</name>
<name>
<surname>Schwarzfischer</surname> <given-names>L</given-names>
</name>
<name>
<surname>Rehli</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Interleukin-4 induced interferon regulatory factor (Irf) 4 participates in the regulation of alternative macrophage priming</article-title>. <source>Immunobiology</source> (<year>2010</year>) <volume>215</volume>:<page-range>821&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.IMBIO.2010.05.031</pub-id>
</citation>
</ref>
<ref id="B96">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>SW</given-names>
</name>
<name>
<surname>Cho</surname> <given-names>EH</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>SY</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>YK</given-names>
</name>
<name>
<surname>Park</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>MK</given-names>
</name>
<etal/>
</person-group>. <article-title>DC-SIGN expression in hofbauer cells may play an important role in immune tolerance in fetal chorionic villi during the development of preeclampsia</article-title>. <source>J Reprod Immunol</source> (<year>2017</year>) <volume>124</volume>:<page-range>30&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.JRI.2017.09.012</pub-id>
</citation>
</ref>
<ref id="B97">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname> <given-names>B</given-names>
</name>
<name>
<surname>Wehling-Henricks</surname> <given-names>M</given-names>
</name>
<name>
<surname>Villalta</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tidball</surname> <given-names>JG</given-names>
</name>
</person-group>. <article-title>IL-10 triggers changes in macrophage phenotype that promote muscle growth and regeneration</article-title>. <source>J Immunol</source> (<year>2012</year>) <volume>189</volume>:<page-range>3669&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/JIMMUNOL.1103180</pub-id>
</citation>
</ref>
<ref id="B98">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sulahian</surname> <given-names>TH</given-names>
</name>
<name>
<surname>H&#xf6;gger</surname> <given-names>P</given-names>
</name>
<name>
<surname>Wahner</surname> <given-names>AE</given-names>
</name>
<name>
<surname>Wardwell</surname> <given-names>K</given-names>
</name>
<name>
<surname>Goulding</surname> <given-names>NJ</given-names>
</name>
<name>
<surname>Sorg</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Human monocytes express cd163, which is upregulated by il-10 and identical TO p155</article-title>. <source>Cytokine</source> (<year>2000</year>) <volume>12</volume>:<page-range>1312&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1006/CYTO.2000.0720</pub-id>
</citation>
</ref>
<ref id="B99">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gray</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Poljakovic</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kepka-Lenhart</surname> <given-names>D</given-names>
</name>
<name>
<surname>Morris</surname> <given-names>SM</given-names>
</name>
</person-group>. <article-title>Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBP&#x3b2;</article-title>. <source>Gene</source> (<year>2005</year>) <volume>353</volume>:<fpage>98</fpage>&#x2013;<lpage>106</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.GENE.2005.04.004</pub-id>
</citation>
</ref>
<ref id="B100">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>WK</given-names>
</name>
<name>
<surname>Georgiadis</surname> <given-names>A</given-names>
</name>
<name>
<surname>Copland</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Liyanage</surname> <given-names>S</given-names>
</name>
<name>
<surname>Luhmann</surname> <given-names>UFO</given-names>
</name>
<name>
<surname>Robbie</surname> <given-names>SJ</given-names>
</name>
<etal/>
</person-group>. <article-title>IL-4 regulates specific arg-1+ macrophage sFlt-1&#x2013;mediated inhibition of angiogenesis</article-title>. <source>Am J Pathol</source> (<year>2015</year>) <volume>185</volume>:<page-range>2324&#x2013;35</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.AJPATH.2015.04.013</pub-id>
</citation>
</ref>
<ref id="B101">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Patel</surname> <given-names>D</given-names>
</name>
<name>
<surname>Morris</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Rutschman</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Murray</surname> <given-names>PJ</given-names>
</name>
</person-group>. <article-title>Shaping gene expression in activated and resting primary macrophages by IL-10</article-title>. <source>J Immunol</source> (<year>2002</year>) <volume>169</volume>:<page-range>2253&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/JIMMUNOL.169.5.2253</pub-id>
</citation>
</ref>
<ref id="B102">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schottelius</surname> <given-names>AJG</given-names>
</name>
<name>
<surname>Mayo</surname> <given-names>MW</given-names>
</name>
<name>
<surname>Balfour Sartor</surname> <given-names>R</given-names>
</name>
<name>
<surname>Baldwin</surname> <given-names>AS</given-names>
</name>
</person-group>. <article-title>Interleukin-10 signaling blocks inhibitor of &#x3ba;B kinase activity and nuclear factor &#x3ba;B DNA binding *</article-title>. <source>J Biol Chem</source> (<year>1999</year>) <volume>274</volume>:<page-range>31868&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/JBC.274.45.31868</pub-id>
</citation>
</ref>
<ref id="B103">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalmas</surname> <given-names>E</given-names>
</name>
<name>
<surname>Toubal</surname> <given-names>A</given-names>
</name>
<name>
<surname>Alzaid</surname> <given-names>F</given-names>
</name>
<name>
<surname>Blazek</surname> <given-names>K</given-names>
</name>
<name>
<surname>Eames</surname> <given-names>HL</given-names>
</name>
<name>
<surname>Lebozec</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity</article-title>. <source>Nat Med</source> (<year>2015</year>) <volume>21</volume>:<page-range>610&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nm.3829</pub-id>
</citation>
</ref>
<ref id="B104">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mosser</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Hamidzadeh</surname> <given-names>K</given-names>
</name>
<name>
<surname>Goncalves</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Macrophages and the maintenance of homeostasis</article-title>. <source>Cell Mol Immunol</source> (<year>2020</year>) <volume>18</volume>:<page-range>579&#x2013;87</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41423-020-00541-3</pub-id>
</citation>
</ref>
<ref id="B105">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>A-Gonzalez</surname> <given-names>N</given-names>
</name>
<name>
<surname>Bensinger</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>C</given-names>
</name>
<name>
<surname>Beceiro</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bradley</surname> <given-names>MN</given-names>
</name>
<name>
<surname>Zelcer</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR</article-title>. <source>Immunity</source> (<year>2009</year>) <volume>31</volume>:<page-range>245&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/J.IMMUNI.2009.06.018</pub-id>
</citation>
</ref>
<ref id="B106">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kourtzelis</surname> <given-names>I</given-names>
</name>
<name>
<surname>Hajishengallis</surname> <given-names>G</given-names>
</name>
<name>
<surname>Chavakis</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Phagocytosis of apoptotic cells in resolution of inflammation</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>553/BIBTEX</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/FIMMU.2020.00553/BIBTEX</pub-id>
</citation>
</ref>
<ref id="B107">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname> <given-names>D</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>W</given-names>
</name>
<name>
<surname>Yi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Groffen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Heisterkamp</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>TGF&#x3b2; signaling plays a critical role in promoting alternative macrophage activation</article-title>. <source>BMC Immunol</source> (<year>2012</year>) <volume>13</volume>:<fpage>1</fpage>&#x2013;<lpage>10</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1471-2172-13-31</pub-id>
</citation>
</ref>
<ref id="B108">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oishi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Manabe</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>Macrophages in inflammation, repair and regeneration</article-title>. <source>Int Immunol</source> (<year>2018</year>) <volume>30</volume>:<page-range>511&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/INTIMM/DXY054</pub-id>
</citation>
</ref>
<ref id="B109">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanania</surname> <given-names>R</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>HS</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>K</given-names>
</name>
<name>
<surname>Pustylnik</surname> <given-names>S</given-names>
</name>
<name>
<surname>Jeganathan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Harrison</surname> <given-names>RE</given-names>
</name>
</person-group>. <article-title>Classically activated macrophages use stable microtubules for matrix metalloproteinase-9 (MMP-9) secretion</article-title>. <source>J Biol Chem</source> (<year>2012</year>) <volume>287</volume>:<page-range>8468&#x2013;83</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/JBC.M111.290676/ATTACHMENT/13099993-EBF4-49E0-A71C-77C3089A9E06/MMC1.PDF</pub-id>
</citation>
</ref>
<ref id="B110">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yuan</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhen</surname> <given-names>G</given-names>
</name>
<name>
<surname>Crane</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Transforming growth factor-&#x3b2; in stem cells and tissue homeostasis</article-title>. <source>Bone Res</source> (<year>2018</year>) <volume>6</volume>:<fpage>1</fpage>&#x2013;<lpage>31</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41413-017-0005-4</pub-id>
</citation>
</ref>
<ref id="B111">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobayashi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Sugiura</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kohyama</surname> <given-names>T</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>Q</given-names>
</name>
<etal/>
</person-group>. <article-title>Matrix metalloproteinase-9 activates TGF-&#x3b2; and stimulates fibroblast contraction of collagen gels</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> (<year>2014</year>) <volume>306</volume>:<fpage>L1006</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/AJPLUNG.00015.2014</pub-id>
</citation>
</ref>
<ref id="B112">
<label>112</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zajac</surname> <given-names>E</given-names>
</name>
<name>
<surname>Schweighofer</surname> <given-names>B</given-names>
</name>
<name>
<surname>Kupriyanova</surname> <given-names>TA</given-names>
</name>
<name>
<surname>Juncker-Jensen</surname> <given-names>A</given-names>
</name>
<name>
<surname>Minder</surname> <given-names>P</given-names>
</name>
<name>
<surname>Quigley</surname> <given-names>JP</given-names>
</name>
<etal/>
</person-group>. <article-title>Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9</article-title>. <source>Blood</source> (<year>2013</year>) <volume>1122</volume>(<issue>25</issue>):<page-range>4054&#x2013;67</page-range>. doi: <pub-id pub-id-type="doi">10.1182/BLOOD-2013-05-501494</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>
